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   Increasing	  evidence	  implicates	  the	  presence	  of	  bacteria	  in	  intrauterine	  tissues	  as	  an	  important	  risk	  factor	  for	  spontaneous	  preterm	  labor.	  Epigenetic	  alterations	  of	  innate	  immunity	  genes	  may	  increase	  the	  mother’s	  sensitivity	  to	  subclinical	  levels	  of	  bacteria.	  This	  study	  examined	  the	  presence	  of	  TET2,	  TLR-­‐2,	  and	  TLR-­‐9	  in	  intrauterine	  tissue,	  and	  evaluated	  whether	  epigenetic	  alterations	  of	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  well	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  changed	  their	  expression	  in	  human	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  and	  a	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  cell	  culture.	  Immunohistochemicalstaining	  was	  used	  to	  detect	  the	  
	  
presence	  of	  these	  proteins	  in	  intrauterine	  tissue.	  Gene	  expression	  changes	  were	  evaluated	  in	  stimulated	  monocytes	  and	  macrophages.	  Fluorescence	  immunohistochemistry	  was	  used	  to	  track	  translocation	  of	  TET2	  in	  stimulated	  monocytes	  and	  macrophages.	  Secreted	  IL-­‐8	  concentration	  was	  detected	  with	  ELISA.	  Decidual	  expression	  of	  TET2,	  TLR-­‐2,	  and	  TLR-­‐9	  increased	  in	  the	  order	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  <	  TL	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  found	  that	  TET2,	  TLR-­‐2,	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  and	  IL-­‐8	  are	  regulated	  by	  epigenetic	  mechanisms.	  This	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  the	  first	  to	  report	  activation	  of	  TET2	  involves	  its	  translocation	  from	  the	  cytosol	  to	  the	  nucleus	  in	  macrophages.	  	  












CHAPTER	  1:	  Introduction	  	  
A.	  General	  background	  	  Preterm	  birth	  (PTB)	  is	  defined	  as	  birth	  before	  37	  weeks	  of	  gestation	  1	  and	  has	  been	  described	  as	  a	  “complex,	  multi-­‐factorial	  disorder”	  2.	  The	  incidence	  rate	  of	  PTB	  in	  the	  United	  States	  is	  12.5%	  (2004)	  3.	  The	  number	  of	  PTBs	  has	  increased	  by	  as	  much	  as	  31%	  in	  this	  country	  alone	  since	  the	  early	  1980’s	  4.	  Preterm	  birth	  is	  responsible	  for	  as	  many	  as	  75%	  of	  perinatal	  deaths,	  making	  it	  a	  leading	  cause	  of	  neonatal	  morbidity	  and	  mortality	  5.	  There	  is	  a	  disproportionately	  higher	  rate	  of	  PTB	  in	  African-­‐American	  women	  (17.8%)	  compared	  to	  other	  ethnicities,	  such	  as	  Asian	  and	  Pacific	  Islander	  (10.5%)	  and	  Caucasian	  (11.5%)	  women	  3.	  In	  addition	  to	  causing	  adverse	  effects	  on	  neonatal	  and	  maternal	  health,	  PTB	  costs	  the	  United	  States	  approximately	  $26.2	  billion	  per	  year	  6.	  	  	  	   The	  risk	  factors	  for	  preterm	  labor	  (PTL)	  can	  be	  divided	  into	  four	  general	  categories:	  i)	  maternal	  health,	  ii)	  socioeconomic	  circumstances,	  iii)	  pregnancy-­‐associated	  risks,	  and	  iv)	  idiopathic.	  Possible	  risk	  factors	  with	  respect	  to	  maternal	  health	  include	  maternal	  illness	  (acute	  and	  chronic),	  low	  body	  mass	  index	  (BMI),	  family	  history,	  maternal	  abnormalities,	  and	  stress.	  Acute	  maternal	  illness	  refers	  to	  any	  trauma	  experienced	  by	  the	  mother	  3.	  Chronic	  illnesses	  may	  include	  hypertension,	  diabetes,	  hyperthyroidism,	  asthma,	  heart	  disease,	  restrictive	  lung	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disease,	  and	  many	  others.	  Low	  body	  mass	  index	  (BMI)	  is	  often	  associated	  with	  low	  levels	  of	  essential	  vitamins	  and	  minerals,	  which	  in	  turn	  may	  increase	  susceptibility	  to	  PTL	  1.	  There	  is	  evidence	  of	  positive	  genetic	  correlation	  between	  mothers	  who	  deliver	  preterm	  and	  whether	  they	  themselves	  were	  delivered	  preterm.	  Also	  a	  previous	  preterm	  birth	  increases	  the	  risk	  the	  mother	  will	  have	  another	  preterm	  birth.	  Voltolini,	  et	  al.	  report	  that	  psychological	  stress	  experienced	  by	  the	  mother	  is	  an	  important	  risk	  factor	  for	  PTB	  1.	  Finally,	  maternal	  abnormalities	  include	  shortening	  of	  the	  cervix	  and	  elevated	  fetal	  fibronectin	  levels	  5.	  Examples	  of	  risk	  factors	  in	  the	  second	  category,	  socioeconomic	  circumstances,	  include	  differences	  in	  rates	  of	  PTB	  among	  various	  races	  where	  African-­‐American	  women	  are	  much	  more	  likely	  to	  experience	  PTB	  than	  women	  of	  other	  ethnicities,	  and	  women	  of	  low	  income	  and	  marital	  status	  of	  single	  are	  much	  more	  likely	  to	  experience	  PTB	  1.	  In	  the	  third	  category,	  pregnancy-­‐associated	  risks	  include	  multiple	  pregnancies	  (especially	  via	  in	  vitro	  fertilization),	  short	  interval	  between	  subsequent	  gestations,	  infection,	  uterine	  over-­‐distension,	  hemorrhage,	  and	  fetal	  abnormalities	  1,	  3.	  Lastly,	  idiopathic	  PTBs	  do	  not	  fall	  under	  any	  of	  these	  categories	  and	  phenotype	  does	  not	  express	  any	  of	  the	  aforementioned	  risk	  factors	  6.	  Forty-­‐45%	  of	  all	  PTBs	  are	  a	  result	  of	  spontaneous	  preterm	  labor	  (sPTL),	  which	  is	  currently	  regarded	  as	  idiopathic	  5.	  Since	  essential	  components	  of	  various	  organ	  systems	  develop	  throughout	  gestation,	  preterm	  neonates	  born	  earlier	  in	  gestation	  have	  greater	  risk	  of	  infant	  mortality	  and	  experiencing	  developmental	  complications	  and	  other	  health	  problems	  than	  those	  born	  at	  higher	  gestational	  ages.	  Infant	  mortality	  is	  greatest	  for	  neonates	  born	  before	  32	  weeks	  of	  gestation.	  Neonates	  may	  experience	  any	  of	  the	  following	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complications	  named	  by	  the	  National	  Institute	  of	  Medicine:	  “acute	  respiratory,	  gastrointestinal,	  immunologic,	  central	  nervous	  system,	  hearing	  and	  vision	  problems,	  as	  well	  as	  longer-­‐term	  motor,	  cognitive,	  visual,	  hearing,	  behavioral,	  social-­‐emotional,	  health,	  and	  growth	  problems”	  3.	  According	  to	  Goldenberg,	  Saigal,	  and	  colleagues,	  it	  is	  important	  to	  differentiate	  the	  complications	  faced	  by	  early	  preterm	  births	  versus	  late	  preterm	  births.	  They	  associate	  percentages	  of	  PTBs	  with	  four	  gestational	  ages:	  extreme	  prematurity	  (<28	  weeks,	  5%	  PTB	  births),	  severe	  prematurity	  (28-­‐31	  weeks,	  15%),	  moderate	  prematurity	  (32-­‐33	  weeks,	  20%),	  and	  late	  term	  (34-­‐36	  weeks,	  60-­‐70%)	  5.	  	  Even	  though	  long-­‐term	  effects	  of	  PTB	  for	  late	  term	  neonates	  has	  not	  been	  as	  well	  studied	  as	  those	  for	  early	  term,	  some	  educational	  and	  behavioral	  impediments	  have	  been	  reported.	  One	  study	  observed	  difficulties	  with	  “motor	  skills,	  speaking,	  writing,	  mathematics,	  behavior,	  and	  physical	  education”	  4.	  Consequences	  of	  PTB	  to	  extremely	  premature,	  severely	  premature,	  and	  moderately	  premature	  persons	  are	  much	  more	  severe	  and	  varied	  than	  late	  term.	  Neurodevelopmental	  and	  chronic	  health	  issues	  are	  more	  common	  in	  infancy	  and	  childhood,	  but	  problems	  regarding	  behavior	  and	  other	  higher	  motor	  functions	  become	  increasingly	  evident	  in	  adolescent	  and	  adulthood.	  Despite	  these	  issues,	  however,	  many	  preterm	  babies	  do	  develop	  normally.	  Abnormalities	  in	  neurodevelopment	  include	  cerebral	  palsy,	  sensory	  impairments,	  mental	  retardation,	  other	  unspecified	  “lags,”	  minor	  neuromotor	  dysfunction,	  and	  poor	  coordination.	  A	  few	  studies	  have	  shown	  that	  cerebral	  palsy	  increases	  with	  decreased	  gestational	  age.	  Poor	  coordination	  in	  the	  form	  of	  decreased	  gross	  and	  fine	  motor	  skills	  can	  be	  present	  in	  children	  with	  no	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other	  neurodevelopmental	  problems.	  Studies	  in	  the	  educational	  development	  of	  extremely	  preterm	  children	  show	  cognitive	  sequelae	  in	  the	  form	  of	  poor	  academic	  achievements,	  necessity	  for	  extra	  attention	  at	  school,	  and	  poor	  grades.	  Behaviorally,	  these	  children	  also	  present	  reduced	  visual	  processing	  and	  executive	  function.	  Executive	  function	  is	  referred	  to	  as	  the	  integrated	  behavior	  and	  functions	  carried	  out	  as	  a	  result	  of	  cognitive,	  social	  and	  emotional	  thinking.	  Saigal,	  et	  al.	  make	  an	  important	  distinction	  between	  deficits	  and	  impairments.	  They	  suggest	  that	  most	  extremely	  preterm	  children	  suffer	  from	  deficits	  not	  impairments.	  In	  addition,	  recent	  studies	  have	  shown	  that	  very	  preterm	  infants	  are	  2.6-­‐4.0	  times	  more	  likely	  to	  develop	  attention	  deficit	  hyperactivity	  disorder	  than	  normal	  term	  infants.	  Preterm	  infants	  and	  adolescents	  are	  also	  observed	  to	  be	  shy,	  unassertive,	  anxious,	  withdrawn,	  and	  socially	  maladaptive.	  The	  number	  of	  overall	  health	  problems	  of	  very	  preterm	  infants	  of	  1-­‐2	  years	  is	  increased	  and	  result	  in	  increased	  hospital	  visits.	  More	  than	  50%	  were	  admitted	  due	  to	  respiratory	  illnesses.	  The	  10-­‐12	  year	  age	  group	  also	  requires	  increased	  medical	  attention.	  Teenagers	  and	  adults	  did	  not	  show	  an	  increased	  medical	  dependency	  with	  respect	  to	  chronic	  or	  acute	  illnesses	  and	  quality	  of	  life	  is	  the	  same	  compared	  to	  persons	  born	  at	  normal	  term	  4.	  
	  
B.	  Preterm	  labor	  
	   Normal	  term	  labor	  is	  a	  carefully	  timed	  process	  that	  occurs	  at	  approximately	  40	  weeks	  of	  gestation	  1.	  Four	  phases	  of	  uterine	  activity	  that	  have	  been	  characterized	  are	  quiescence,	  activation,	  stimulation,	  and	  involution	  7.	  Though	  heavily	  researched,	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the	  exact	  events	  leading	  to	  parturition	  and	  labor	  have	  not	  been	  fully	  determined.	  It	  is	  known	  that	  towards	  the	  end	  of	  gestation,	  the	  formation	  of	  gap	  junctions	  between	  discrete	  myocytes	  provides	  a	  mean	  by	  which	  the	  quiescent	  uterus	  becomes	  active.	  Gap	  junctions	  cause	  the	  uterus	  to	  turn	  into	  an	  electrical	  syncytium,	  allowing	  for	  coordinated	  myometrial	  contractions	  by	  way	  of	  synchronous	  myocyte	  activity.	  Hormones	  and	  other	  regulators	  of	  labor	  that	  are	  important	  include	  prostaglandins	  (PG),	  intracellular	  calcium,	  oxytocin	  (OT),	  phospholipase	  C,	  proinflammatory	  cytokines,	  progesterone,	  and	  corticotropin-­‐releasing	  hormone	  (CRH)	  1.	  Maintenance	  of	  pregnancy	  is	  done	  by	  progesterone	  and	  CRH.	  In	  a	  phenomenon	  called	  progesterone	  withdrawal,	  progesterone	  remains	  at	  elevated	  levels	  throughout	  gestation,	  as	  well	  as	  labor.	  However,	  at	  the	  onset	  of	  labor	  its	  levels	  are	  functionally	  reduced	  due	  to	  a	  change	  in	  the	  expression	  levels	  of	  its	  two	  receptors,	  PR-­‐A	  and	  PR-­‐B.	  It	  is	  reported	  that	  PR-­‐A	  expression	  level	  increases	  significantly	  during	  labor	  whereas	  PR-­‐B	  level	  is	  perhaps	  suppressed	  resulting	  in	  a	  change	  in	  the	  ratio	  favoring	  PR-­‐A.	  This	  causes	  expression	  of	  estrogen	  receptor	  to	  rise	  1.	  Progesterone	  withdrawal	  was	  first	  observed	  in	  sheep	  5.	  CRH	  maintains	  pregnancy	  by	  regulating	  the	  length	  of	  gestation	  via	  “autrocrine,	  paracrine,	  and	  endocrine	  mechanisms.”	  It	  is	  produced	  primarily	  by	  the	  placenta	  1.	  Labor	  is	  the	  balance	  of	  two	  systems	  that	  work	  in	  opposition	  –	  one	  that	  promotes	  contraction	  and	  the	  other	  that	  promotes	  relaxation	  1.	  Onset	  of	  labor	  also	  involves	  the	  establishment	  of	  a	  positive	  feedback	  loop	  of	  cytokine	  production.	  At	  the	  start	  of	  contractions,	  leukocytes,	  including	  macrophages	  and	  neutrophils,	  infiltrate	  maternal	  tissue,	  placenta,	  and	  fetal	  membranes,	  become	  activated,	  and	  secrete	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proinflammatory	  cytokines.	  It	  is	  important	  to	  note	  that	  leukocytes	  arrive	  and	  become	  activated	  even	  without	  the	  presence	  of	  infection.	  Cytokines	  associated	  with	  labor	  onset	  include	  IL-­‐1,	  IL-­‐6,	  IL-­‐8,	  and	  TNF-­‐α.	  The	  presence	  of	  these	  cytokines	  signals	  recruitment	  of	  additional	  leukocytes	  to	  the	  area,	  creating	  the	  positive	  feedback	  loop.	  Cytokines	  also	  initiate	  the	  upregulation	  of	  prostaglandins,	  enzymes,	  MMPs,	  and	  other	  regulators	  of	  labor	  7.	  Preterm	  labor	  can	  be	  divided	  into	  four	  types:	  i)	  spontaneous	  PTL	  (sPTL),	  ii)	  infected	  PTL	  (iPTL),	  iii)	  sPTL	  with	  preterm	  premature	  rupture	  of	  the	  membranes	  (pPROM),	  and	  iv)	  iPTL	  with	  pPROM.	  The	  frequency	  of	  iPTL	  is	  30-­‐35%,	  sPTL	  is	  40-­‐45%,	  and	  the	  remaining	  25-­‐30%	  is	  due	  to	  pPROM.	  The	  term	  pPROM	  refers	  to	  the	  condition	  when	  the	  fetal	  membranes	  rupture	  spontaneously	  at	  least	  one	  hour	  before	  contractions	  begin.	  Vaginal	  or	  caesarian	  section	  delivery	  after	  pPROM	  can	  occur	  within	  several	  days,	  weeks	  or	  months.	  The	  later	  two	  are	  relatively	  uncommon	  	  5.	  Infected	  PTL	  is	  due	  to	  intrauterine	  bacteria	  present	  within	  the	  choriodecidual	  space,	  space	  between	  amnion	  and	  chorion	  (chorioamnionitis),	  or	  amniotic	  fluid	  (amnionitis)	  8.	  Evidence	  of	  bacteria	  is	  detected	  through	  histological	  or	  pathological	  methods.	  It	  is	  interesting	  to	  note	  that	  standard	  laboratory	  bacterial	  culture	  techniques	  are	  limited	  in	  their	  scope,	  which	  makes	  identifying	  every	  individual	  bacterial	  strain	  in	  iPTL	  difficult	  9.	  One	  study	  by	  Jones	  et	  al.	  used	  16S	  rDNA	  endpoint	  PCR	  to	  identify	  bacterial	  strains.	  They	  found	  that	  Ureaplasma	  parvum,	  Fusobacterium	  spp,	  Streptococcus	  agalactiae	  and	  Lactobacillus	  crispatus	  are	  common	  to	  PTL	  both	  with	  and	  without	  pPROM	  10.	  In	  general,	  bacteria	  associated	  with	  PTL	  are	  also	  inhabitants	  of	  the	  vaginal	  microbiome	  8.	  Four	  pathways	  by	  which	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bacteria	  can	  make	  their	  way	  to	  the	  uterus	  are:	  (i)	  travel	  from	  the	  vagina	  through	  the	  cervix	  and	  reach	  the	  placental	  membranes	  and	  eventually	  the	  amniotic	  sac,	  (ii)	  bacteria	  from	  the	  maternal	  bloodstream	  can	  cross	  the	  material-­‐fetal	  placental	  barrier	  to	  infect	  the	  placental	  membranes	  and	  eventually	  the	  amniotic	  sac,	  iii)	  retrograde	  transport	  from	  the	  fallopian	  tubes,	  and	  iv)	  unintentional	  introduction	  by	  routine	  pre-­‐natal	  care	  procedures	  such	  as	  amniocentesis,	  chorionic	  villous	  sampling,	  and	  percutaneous	  fetal	  blood	  sampling	  	  5,	  10,	  11.	  The	  most	  common	  route	  is	  ascent	  through	  the	  vagina.	  In	  the	  proposed	  route,	  first,	  there	  is	  a	  change	  in	  the	  vaginal	  flora	  and	  a	  possible	  increase	  of	  pathogenic	  species,	  the	  bacteria	  then	  travel	  to	  the	  decidua	  and	  cause	  inflammation,	  a	  particular	  subset	  of	  that	  population	  then	  crosses	  the	  mucosal	  membranes	  and	  reach	  the	  chorion	  and	  amnion,	  and	  finally,	  invade	  the	  amniotic	  cavity.	  pPROM	  may	  or	  may	  not	  occur	  during	  the	  final	  step	  8.	  	  	   Conversely,	  sPTL	  has	  a	  pathogenesis	  that	  is	  much	  more	  complicated	  and	  not	  yet	  fully	  understood.	  Recent	  studies	  report	  that	  the	  presence	  of	  bacteria	  alone	  is	  not	  enough	  to	  explain	  preterm	  labor.	  Jones	  et	  al.	  showed	  with	  16S	  rDNA	  PCR	  that	  90%	  of	  their	  PTL	  tissue	  samples	  of	  patients	  with	  intact	  membranes	  tested	  positive	  for	  at	  least	  one	  bacterial	  strain;	  whereas,	  73%	  pPROM	  (vaginal	  birth)	  and	  55%	  pPROM	  (caesarian	  section)	  tested	  positive	  10.	  A	  study	  by	  Stout	  et	  al.	  found	  that	  54%	  of	  patient	  samples	  from	  women	  with	  sPTB	  and	  pPROM	  contained	  intracellular	  bacteria.	  sPTB	  with	  pPROM	  was	  defined	  as	  any	  case	  where	  PTB	  prior	  to	  37	  weeks	  of	  gestation	  was	  not	  explained	  by	  preeclampsia,	  abriptio	  placentae,	  or	  intrauterine	  growth	  restriction.	  Bacteria	  were	  detected	  by	  Gram	  staining	  followed	  by	  image	  analysis	  12.	  Romero	  et	  al.	  have	  presented	  evidence	  linking	  PTL	  with	  subclinical	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infection	  9.	  Mounting	  evidence	  strongly	  suggests	  that	  the	  presence	  of	  bacteria	  alone	  is	  not	  enough	  to	  explain	  sPTL.	  The	  specific	  mechanisms	  that	  ultimately	  lead	  to	  sPTL	  are	  still	  unclear,	  but	  the	  most	  widely	  accepted	  view	  states	  that	  sPTL	  results	  from	  pathological	  processes	  that	  prematurely	  activate	  the	  same	  mechanisms	  that	  lead	  to	  normal	  term	  labor	  1.	  A	  specific	  prematurely	  activating	  component	  has	  not	  yet	  been	  found,	  but	  research	  is	  in	  initial	  stages.	  	  	   Currently,	  no	  cure	  exists	  for	  preterm	  labor	  but	  there	  are	  a	  variety	  of	  treatments	  that	  aim	  to	  prolong	  fetal	  intrauterine	  life	  and	  improve	  quality	  of	  life	  for	  the	  fetus.	  Such	  treatments	  include	  tocolytic	  agents,	  antibiotics,	  corticosteroids,	  progesterone,	  and	  cervical	  cerclage	  1,	  2.	  	  There	  is	  no	  primary	  tocolytic	  agent	  of	  choice	  that	  has	  proven	  most	  effective,	  but	  options	  include	  calcium	  channel	  blockers	  (e.g.	  Nifedipine),	  magnesium	  sulfate,	  cyclooxygenase	  (COX)	  inhibitors,	  beta	  mimetics,	  and	  OT-­‐receptor	  antagonists	  1.	  Though	  this	  type	  of	  treatment	  does	  not	  prevent	  PTL,	  it	  delays	  birth	  for	  a	  few	  days.	  This	  creates	  time	  for	  administering	  corticosteroids,	  transferring	  the	  mother	  to	  a	  facility	  equipped	  to	  handle	  such	  cases,	  and	  monitoring	  the	  health	  of	  both	  the	  fetus	  and	  mother	  1,	  2.	  	  Antibiotics	  do	  not	  offer	  any	  advantages	  to	  women	  with	  sPTL	  and	  intact	  membranes;	  however,	  they	  may	  reduce	  infection	  in	  cases	  with	  pPROM.	  Coricosteroids	  (e.g.	  betamethasone	  and	  dexamethasone)	  help	  decrease	  morbidity	  and	  mortality	  of	  newborns	  because	  they	  aid	  fetal	  lung	  maturation	  1.	  Progesterone	  has	  been	  shown	  to	  reduce	  instances	  of	  PTL	  under	  certain	  circumstances,	  but	  side-­‐effects	  are	  unknown	  2.	  Cervical	  cerclage	  is	  a	  procedure	  that	  sutures	  the	  opening	  of	  the	  cervix	  to	  prevent	  premature	  delivery	  13.	  It	  is	  generally	  done	  in	  the	  second	  or	  third	  trimester	  and	  is	  primarily	  recommended	  for	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weak	  or	  short	  cervixes	  13,	  14.	  Studies	  suggest	  that	  cervical	  cerclage	  is	  effective	  only	  in	  very	  specific	  cases,	  such	  as	  certain	  high-­‐risk	  ones,	  but	  overall	  does	  not	  show	  significant	  reduction	  in	  preterm	  labor	  15.	  	  
C.	  Origins	  of	  the	  amnion,	  chorion,	  and	  decidua	  
	  
	   Within	  5	  days	  of	  fertilization,	  blastomeres	  give	  rise	  to	  two	  distinct	  cell	  masses	  –	  the	  embryoblast	  and	  trophoblast.	  During	  the	  second	  week	  of	  gestation,	  the	  embryoblast	  divides	  into	  the	  epiblast	  and	  hypoblast.	  At	  this	  point,	  the	  blastocyst	  consists	  of	  these	  two	  layers	  surrounded	  by	  the	  trophoblast.	  The	  amnion	  is	  epiblast	  derived	  because	  this	  group	  of	  cells	  expands	  to	  line	  the	  cavity	  between	  the	  trophoblast	  and	  hypoblast.	  As	  this	  cavity	  expands,	  it	  is	  referred	  to	  as	  the	  amniotic	  sac	  	  16.	  	  	   Meanwhile,	  the	  trophoblast	  is	  also	  made	  up	  of	  two	  distinct	  cell	  masses	  –	  the	  syncytiotrophoblast	  and	  the	  cytotrophoblast.	  The	  latter	  makes	  up	  the	  wall	  of	  the	  blastocyst	  away	  from	  the	  endometrium	  during	  implantation.	  As	  the	  hypoblast	  expands	  to	  fill	  the	  cavity	  between	  the	  epiblast	  and	  the	  cytotrophoblast,	  called	  Heuser’s	  membrane,	  the	  cytotrophoblast	  becomes	  referred	  to	  as	  the	  chorion.	  By	  the	  second	  month	  of	  pregnancy,	  the	  chorion	  is	  composed	  of:	  i)	  chorion	  laeve	  or	  smooth	  chorion,	  which	  loses	  its	  vili	  and	  adjacent	  to	  the	  decidua	  capilaris	  and	  ii)	  chorion	  frondosum,	  which	  retains	  is	  vili	  and	  is	  adjacent	  to	  the	  decidua	  basalis	  	  16.	  	  	   Whereas	  the	  previous	  two	  layers	  are	  of	  fetal	  origin,	  the	  decidua	  is	  of	  maternal	  origin.	  More	  specifically,	  decidual	  cells	  are	  of	  stromal	  origin,	  which	  is	  the	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tissue	  layer	  in	  the	  endometrium	  directly	  under	  the	  epithelium.	  Stromal	  cells	  become	  decidual	  cells	  by	  amassing	  lipid	  and	  glycogen.	  As	  the	  stroma	  enlarges	  and	  becomes	  increasingly	  vascularized,	  it	  is	  referred	  to	  as	  the	  decidua.	  The	  decidua	  is	  made	  up	  of	  the	  decidua	  basalis,	  decidua	  parietalis,	  and	  the	  decidua	  capsularis,	  which	  dissolves	  by	  the	  third	  trimester	  16.	  
	  
D.	  Epigenetics	  	  	  	   Epigenetics	  is	  the	  regulation	  of	  gene	  expression	  not	  mediated	  through	  changes	  in	  DNA	  sequence	  17.	  This	  activity	  is	  important	  for	  processes	  such	  as	  normal	  embryonic	  development	  (e.g.	  tissue-­‐specific	  gene	  regulation),	  cellular	  differentiation,	  X-­‐chromosome	  inactivation,	  and	  genomic	  imprinting	  17-­‐19.	  Epigenetic	  changes	  are	  mitotically	  heritable	  and	  modulate	  when	  and	  where	  certain	  genes	  are	  expressed.	  This	  modulation	  is	  conserved	  by	  many	  proteins	  that	  work	  in	  concert	  to	  either	  allow	  or	  prevent	  transcription	  factors,	  cofactors	  and	  scaffolding	  proteins	  to	  access	  DNA	  at	  specific	  points	  along	  the	  sequence.	  Some	  epigenetic	  modifications	  show	  plasticity,	  whereas,	  others	  remain	  stable	  long-­‐term	  19.	  Cells	  exhibit	  epigenetic	  plasticity	  by	  modifying	  phenotype	  in	  response	  to	  environmental	  signals	  20,	  such	  as	  nutrition	  21,	  disease	  	  20,	  age,	  and	  oxidative	  stress.	  A	  few	  examples	  of	  mechanisms	  that	  contribute	  to	  epigenetic	  changes	  include	  DNA	  methylation,	  histone	  modification,	  and	  non-­‐coding	  RNAs	  19.	  DNA	  methylation	  is	  of	  most	  interest	  with	  respect	  to	  preterm	  labor.	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In	  mammalian	  DNA	  methylation,	  methyl	  groups	  are	  added	  or	  removed	  from	  the	  5’	  carbon	  of	  cytosine	  in	  a	  CpG	  dinucleotide	  17.	  CpG	  dinucleotides	  are	  composed	  of	  a	  cytosine	  linked	  to	  a	  guanine	  via	  a	  sugar	  phosphate	  and,	  although	  found	  throughout	  the	  genome,	  they	  are	  found	  in	  high	  frequency	  clustered	  at	  CpG	  islands.	  CpG	  islands	  are	  sequences	  that	  are	  found	  most	  often	  located	  in	  the	  promoter	  regions	  of	  genes	  and	  can	  stretch	  several	  kilobases	  19.	  A	  particular	  gene	  becomes	  silenced	  when	  methylated	  at	  such	  sites	  and	  becomes	  expressed	  when	  demethylated.	  The	  mechanism	  by	  which	  DNA	  methyltransferases	  facilitate	  the	  conversion	  of	  cytosine	  (C)	  to	  5-­‐methylcytosine	  (5mC)	  is	  fairly	  well	  known	  in	  mammals,	  but	  researchers	  have	  yet	  to	  agree	  on	  one	  for	  DNA	  demethylation	  18.	  DNA	  methylation	  is	  catalyzed	  by	  a	  host	  of	  DNA	  methyltransferases	  (DNMTs)	  that	  have	  the	  ability	  to	  maintain	  methylation	  (DNMT1)	  and	  facilitate	  “de	  novo”	  methylation	  (DNMT3a/DNMT3b)	  19,	  
22.	  	   There	  are	  two	  types	  of	  DNA	  demethylation.	  The	  first,	  global	  nonspecific	  DNA	  demethylation,	  is	  important	  during	  embryonic	  development	  and	  is	  mediated	  by	  excision	  repair	  mechanisms	  18,	  19.	  The	  mechanism	  of	  site-­‐specific	  enzymatic	  demethylation,	  which	  is	  the	  second	  type,	  has	  recently	  been	  discovered.	  Groundbreaking	  evidence	  demonstrates	  that	  a	  family	  of	  ten-­‐eleven-­‐translocation	  proteins	  (TET1-­‐3)	  oxidize	  5mC	  to	  5-­‐hydroxymethylcytosine	  (5hmC)	  where	  the	  methyl	  group	  becomes	  hydroxylated	  23,	  24.	  	  He	  et	  al.	  suggest	  that	  this	  is	  the	  first	  step	  of	  enzymatic	  DNA	  demethylation	  25.	  Consolidating	  data	  from	  several	  groups,	  Nabel	  et	  al.	  further	  suggest	  that	  TET	  enzymes	  also	  catalyze	  iterative	  oxidation	  of	  5hmC	  to	  5-­‐formylcytosine	  (5fC)	  and	  5-­‐carboxylcytosine	  (5caC).	  Lastly,	  unmethylated	  
	  	   12	  
cytosine	  replaces	  the	  oxidized	  methylcytosine	  (mC)	  by	  base	  excision	  repair	  mechanisms	  catalyzed	  by	  thymine-­‐DNA	  glycosylase	  (TGD).	  During	  this	  step	  the	  oxidized	  methyl	  group	  is	  cleaved	  24.	  Within	  the	  TET	  family	  of	  enzymes,	  TET3	  is	  most	  involved	  in	  oxidation	  of	  5mC	  in	  the	  zygote	  following	  fertilization,	  whereas,	  TET2	  activity	  is	  documented	  in	  primary	  human	  monocytes	  18.	  	  
E.	  Innate	  immunity	  &	  Toll-­‐like	  receptors	  	  	   The	  human	  immune	  system	  has	  two	  parts	  –	  innate	  and	  adaptive	  immunity.	  Innate	  immunity	  is	  a	  relatively	  immediate	  response	  to	  invasion	  of	  microbes,	  whereas,	  adaptive	  immunity	  mounts	  a	  response	  4-­‐7	  days	  after	  initial	  infection.	  Innate	  immunity	  is	  composed	  of	  three	  types	  of	  barriers	  for	  pathogens:	  i)	  mechanical	  (e.g.	  epithelial	  layer,	  tears,	  mucous,	  and	  cilia	  in	  air	  passageways),	  ii)	  chemical	  (e.g.	  fatty	  acids	  in	  sweat,	  low	  pH	  of	  saliva,	  low	  pH	  of	  bile	  acids,	  and	  presence	  of	  lysozyme	  and	  phospholipase	  in	  tears),	  iii)	  biological	  (e.g.	  inflammatory	  response,	  and	  normal	  flora	  of	  skin,	  oral	  cavity,	  gastrointestinal	  tract,	  and	  vagina).	  The	  inflammatory	  response	  is	  mediated	  by	  specific	  cells	  including	  macrophages,	  dendritic	  cells,	  neutrophils,	  natural	  killer	  cells,	  and	  eosinophils	  26.	  The	  most	  well-­‐known	  class	  of	  receptors	  in	  innate	  immunity	  are	  pattern	  recognition	  receptors	  (PRRs),	  which	  are	  surface	  receptors	  that	  detect	  conserved	  features	  of	  bacteria,	  viruses,	  fungi,	  and	  protozoans	  27	  called	  pathogen	  associated	  molecular	  patterns	  (PAMPs)	  28,	  29.	  These	  conserved	  features	  are	  detected	  as	  non-­‐self	  because	  they	  are	  not	  present	  in	  the	  host	  
30.	  Secreted,	  cytosolic,	  and	  transmembrane	  are	  the	  three	  distinct	  classes	  of	  PRRs,	  of	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which,	  toll-­‐like	  receptors	  (TLRs)	  belong	  to	  the	  later	  group	  27.	  Other	  types	  of	  PRRs	  include	  nucleotide-­‐binding	  oligomerization	  domain	  (NOD)-­‐like	  receptors	  (NLRs),	  retinoic	  acid-­‐inducible	  gene-­‐1	  (RIG-­‐1)-­‐like	  receptors	  (RLRs),	  and	  C-­‐type	  lectin	  receptors	  (CLRs)	  30.	  In	  addition	  to	  sensing	  PAMPs,	  TLRs	  also	  recognize	  damage	  associated	  molecular	  patterns	  (DAMPs).	  These	  are	  endogenous	  agonists	  produced	  by	  the	  host	  in	  response	  to	  tissue	  damage,	  cell	  damage,	  oxidative	  stress,	  and	  inflammation.	  DAMPs	  allow	  TLRs	  to	  distinguish	  between	  healthy	  and	  damaged	  tissue	  27.	  	  	   TLRs	  1,	  2,	  4,	  5,	  6,	  and	  10	  are	  localized	  on	  the	  cell	  surface	  where	  they	  recognize	  extracellular	  PAMPs	  as	  well	  as	  chemical	  signals	  released	  by	  invading	  pathogens.	  TLRs	  3,	  7,	  8,	  and	  9	  are	  localized	  within	  the	  interior	  of	  a	  cell	  on	  an	  endosome	  and	  recognize	  nucleic	  acids	  that	  become	  released	  following	  phagocytosis	  
27	  and	  cell	  lysis.	  Currently,	  the	  only	  known	  function	  of	  TLR-­‐1	  is	  its	  heterodimerization	  with	  TLR-­‐2	  following	  binding	  of	  ligands	  such	  as	  tri-­‐acyl-­‐lipopeptide	  from	  bacteria,	  and	  outer	  surface	  proteins	  of	  Borrelia	  species.	  TLR-­‐2	  has	  a	  host	  of	  agonists,	  which	  are	  discussed	  at	  length	  below.	  TLR-­‐3	  recognizes	  double	  stranded	  viral	  RNA	  31	  and	  forms	  a	  homodimer	  upon	  activation	  32.	  The	  primary	  agonist	  of	  TLR-­‐4	  is	  lipopolysaccharide	  (LPS),	  but	  others	  such	  as	  lipoteichoic	  acid,	  fibrinogen,	  heparin	  sulfate,	  heat-­‐shock	  protein	  60	  (HSP60)	  and	  respiratory	  syncytial	  virus	  proteins	  stimulate	  it	  as	  well.	  TLR-­‐5	  recognizes	  flagellin.	  Similar	  to	  TLR-­‐1,	  TLR-­‐6	  forms	  heterodimers	  with	  TLR-­‐2	  in	  the	  presence	  of	  di-­‐acyl-­‐lipopeptides	  from	  Mycoplasma	  and	  zymozan.	  TLRs	  7	  and	  8	  both	  bind	  single	  stranded	  RNA,	  but	  TLR-­‐7	  is	  functional	  in	  mice,	  whereas,	  TLR-­‐8	  is	  functional	  in	  humans.	  TLR-­‐9	  recognizes	  DNA	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present	  in	  bacteria	  and	  viruses.	  This	  receptor	  is	  discussed	  at	  length	  below.	  Lastly,	  although	  efforts	  have	  been	  made	  to	  characterize	  TLR-­‐10,	  its	  absence	  from	  the	  mouse	  genome	  has	  made	  it	  difficult	  to	  elucidate	  its	  function	  in	  humans	  31.	  	  	   Toll-­‐like	  receptors	  are	  type-­‐1	  transmembrane	  proteins	  27	  characterized	  by	  a	  single	  α-­‐helix	  traversing	  the	  cell	  membrane.	  The	  N-­‐terminal	  is	  oriented	  extracellularly	  32	  and	  imparts	  specificity	  to	  each	  TLR	  via	  unique	  motifs	  of	  16-­‐28	  leucine-­‐rich	  repeats	  (LRRs),	  which	  form	  a	  solenoid	  on	  the	  outer	  leaflet	  of	  the	  cell	  membrane	  27,	  32.	  Each	  LRR	  has	  the	  motif	  “LxxLxLxxN”	  which	  stretches	  20-­‐30	  amino	  acids	  32	  and	  functions	  in	  PAMP	  recognition	  33.	  The	  intracellular	  C-­‐terminus	  of	  Toll-­‐like	  receptors	  consists	  of	  the	  Toll/IL-­‐1	  receptor	  (TIR)	  domain.	  The	  sequence	  of	  this	  domain,	  which	  is	  common	  to	  all	  TLRs,	  resembles	  one	  belonging	  to	  the	  IL-­‐1	  receptor	  
34.	  Once	  a	  PAMP	  or	  DAMP	  binds	  the	  extracellular	  domain	  (Fig.	  1),	  the	  TIR	  domain	  becomes	  activated	  and	  recruits	  TIR-­‐domain-­‐containing	  adaptors,	  the	  most	  common	  of	  which	  is	  MyD88	  33	  (myeloid	  differentiation	  antigen	  88)	  27.	  Activation	  of	  the	  TIR	  domain	  occurs	  due	  to	  ligand-­‐induced	  TLR	  dimerization	  or	  oligomerization	  35.	  MyD88	  is	  an	  essential	  component	  of	  the	  canonical	  pathway	  that	  results	  in	  NF-­‐κB	  translocation	  into	  the	  nucleus.	  Other	  adaptor	  proteins	  include	  TIRAP	  (also	  known	  as	  Mal),	  which	  is	  essential	  for	  MyD88	  signaling	  in	  TLRs	  2	  and	  4,	  and	  TRIF	  and	  TRAM,	  which	  are	  essential	  in	  TLRs	  7,	  8,	  and	  9	  for	  non-­‐canonical	  activation	  of	  NF-­‐κB.	  Adaptor	  proteins	  interact	  with	  the	  receptor	  TIR	  domain	  via	  their	  own	  TIR	  domains	  
27.	  In	  the	  canonical	  activation	  of	  NF-­‐κB,	  once	  a	  PAMP	  binds	  the	  extracellular	  domain,	  the	  TIR	  domain	  becomes	  activated,	  recruits	  MyD88,	  which	  in	  turn	  recruits	  the	  IRAK	  family	  of	  kinases	  33.	  The	  exact	  functions	  of	  IRAK	  1-­‐4	  have	  not	  been	  elucidated	  but	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there	  is	  strong	  evidence	  to	  suggest	  that	  IRAK4	  phosphorylates	  IRAK1	  and	  possibly	  IRAK2	  35.	  IRAK1	  and	  IRAK2	  then	  associate	  with	  TRAF6,	  a	  lysine	  63	  (K63)-­‐specific	  E3	  ubiquitin-­‐protein	  ligase,	  which	  complexes	  with	  Ubc13	  and	  Uev1A	  33,	  35.	  This	  complex	  functions	  to	  promote	  K63-­‐polyubiquitination	  and	  subsequent	  activation	  of	  several	  proteins	  including	  TRAF6.	  TRAF6	  and	  IRAK1	  then	  associate	  with	  TAK1	  which	  complexes	  with	  TABs	  1,	  2,	  and	  3.	  Once	  TAK1	  and	  TAB2	  become	  phosphorylated,	  IRAK1	  degrades	  and	  this	  complex	  breaks	  away	  from	  the	  cell	  membrane	  and	  goes	  to	  the	  cytosol.	  TRAF6	  activates	  the	  regulatory	  subunit	  (NEMO/	  IKKλ)	  of	  the	  IKK	  complex	  35.	  The	  activated	  NEMO/	  IKKλ	  subunit	  is	  responsible	  for	  phosphorylation	  of	  IκB	  which	  results	  in	  its	  subsequent	  degradation.	  Degradation	  of	  IκB	  removes	  inhibition	  from	  NF-­‐κB,	  which	  leads	  to	  its	  translocation	  into	  the	  nucleus	  33.	  Once	  in	  the	  nucleus,	  it	  mediates	  upregulation	  of	  a	  range	  of	  proinflammatory	  cytokines	  including	  those	  that	  encode	  tumor	  necrosis	  factors	  (e.g.	  TNF-­‐α),	  chemokines	  (e.g.	  IL-­‐8),	  interleukins	  (e.g.	  IL-­‐6)	  26,	  adhesion	  molecules	  36,	  antimicrobial	  peptides	  (e.g.	  defensins)	  37,	  and	  co-­‐stimulatory	  molecules	  7.	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Figure	  1:	  General	  mechanism	  of	  proinflammatory	  cytokine	  upregulation	  upon	  
stimulation	  of	  TLR-­‐2	  and	  TLR-­‐9	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   It	  is	  important	  to	  note	  that	  this	  is	  just	  one	  of	  the	  ways	  NF-­‐κB	  can	  be	  activated.	  Non-­‐canonical	  pathways	  exist	  as	  well.	  There	  are	  multiple	  ways	  to	  induct	  a	  signal,	  which	  means	  that	  different	  downstream	  transcription	  factors	  and	  cytokines	  can	  be	  activated	  when	  various	  intracellular	  signaling	  pathways	  work	  in	  conjunction	  with	  one	  another.	  Various	  groupings	  of	  adaptor	  molecules	  result	  from	  different	  PAMPs	  and	  TLRs,	  which	  gives	  rise	  to	  different	  downstream	  products.	  The	  ability	  of	  TLRs	  to	  homodimerize	  or	  heterdimerize	  also	  adds	  variety.	  This	  phenomenon	  creates	  variety	  in	  the	  system	  so	  that	  appropriate	  innate	  immune	  responses	  can	  be	  triggered	  27,	  33.	  Another	  important	  note	  about	  the	  TLR	  function	  is	  that	  there	  is	  a	  point	  at	  which	  excessive	  TLR	  activation	  leads	  to	  excessive	  inflammation,	  which	  may	  cause	  the	  host	  to	  undergo	  sepsis,	  tissue	  damage,	  autoimmunity,	  and	  atherosclerosis	  to	  name	  a	  few	  conditions	  27,	  38.	  To	  address	  this	  issue,	  negative	  regulators	  such	  as	  PI3K	  (phosphatidyl	  inositol-­‐3	  kinase)	  work	  to	  reduce	  TLR-­‐mediated	  inflammation	  38.	  In	  addition,	  a	  recent	  review	  by	  the	  Inflammation	  Biology	  Group	  in	  Marseille,	  France	  gathered	  evidence	  to	  suggest	  that	  NF-­‐κB	  itself	  may	  regulate	  proinflammatory,	  as	  well	  as	  anti-­‐inflammatory	  mediators	  36.	  Toll-­‐like	  receptor	  2	  is	  capable	  of	  binding	  diverse	  ligands	  that	  come	  from	  bacteria,	  viruses,	  mycobacteria,	  and	  fungi	  31.	  A	  short	  list	  of	  its	  bacterial	  agonists	  includes	  peptidoglycan	  from	  Gram-­‐positive	  bacteria,	  lipoproteins,	  lipopeptides,	  and	  porins.	  A	  protozoan	  agonist	  is	  glycosyl-­‐phosphatidylinositol-­‐linked	  proteins.	  Zymozan,	  which	  originates	  from	  yeast	  cell	  wall,	  and	  mannans	  are	  examples	  of	  fungal	  agonists	  34.	  Lastly,	  lipoarabinomannan	  is	  an	  example	  of	  a	  mycobacterial	  agonist.	  In	  addition	  to	  functioning	  alone,	  TLR-­‐2	  also	  forms	  heterodimers	  with	  TLR-­‐1	  and	  TLR-­‐6.	  
	  	   18	  
The	  TLR-­‐1/TLR-­‐2	  heterodimer	  recognizes	  triacyl-­‐lipopeptides	  from	  bacteria,	  whereas,	  TLR-­‐1/TLR-­‐6	  recognizes	  diacyl-­‐lipopeptides	  from	  mycoplasma	  and	  zymosan.	  TLR-­‐2	  is	  located	  primarily	  on	  myeloid	  cells,	  T	  cells,	  immune	  effector	  cells,	  epithelial	  cells,	  and	  platelets	  31.	  A	  2004	  study	  by	  Kim,	  et	  al.	  investigated	  expression	  levels	  of	  TLR-­‐2	  and	  TLR-­‐4	  in	  fetal	  membranes	  from	  preterm	  women	  with	  and	  without	  chorioamnionitis.	  Their	  results	  showed	  that	  TLR-­‐2	  is	  expressed	  only	  at	  the	  basal	  portions	  of	  the	  amnion	  in	  PTL	  women	  who	  tested	  negative	  for	  chorioamnionitis.	  Whereas,	  TLR-­‐2	  is	  highly	  expressed	  along	  the	  entire	  length	  of	  the	  amnion	  in	  PTL	  women	  positive	  for	  chorioamnionitis.	  Consequently,	  Kim	  proposed	  that	  this	  “polarized	  distribution”	  of	  TLR-­‐2	  is	  beneficial	  for	  the	  immune	  system	  to	  immediately	  target	  the	  ascending	  infection	  that	  has	  been	  theorized	  in	  cases	  of	  sPTL	  
37.	  	   Toll-­‐like	  receptor	  9	  becomes	  activated	  upon	  stimulation	  with	  bacterial	  and	  viral	  DNA	  and	  unmethylated	  CpG	  dinucleotides	  34.	  Sites	  with	  unmethylated	  CpG’s	  are	  not	  common	  in	  human	  DNA	  but	  are	  widely	  present	  in	  bacteria	  31.	  The	  commercial	  agonist	  for	  TLR-­‐9	  is	  synthetic	  CpG	  oligodeoxynucleotide	  (ODN)	  39.	  In	  vivo,	  it	  is	  not	  known	  how	  TLR-­‐9	  differentiates	  between	  self	  and	  non-­‐self	  DNA;	  however,	  there	  are	  a	  couple	  of	  theories.	  It	  was	  first	  thought	  that	  recognition	  by	  TLR-­‐9	  was	  solely	  dependent	  on	  presence	  of	  CpG	  dinucleotides,	  but	  more	  recent	  studies	  have	  shown	  that	  it	  is	  less	  stringent.	  More	  recent	  work	  predicts	  that	  TLR-­‐9	  binding	  specificity	  is	  more	  so	  determined	  by	  co-­‐localization	  of	  DNA	  to	  the	  endosome	  and	  lysosome	  40.	  Since	  TLR-­‐9	  is	  located	  on	  endosomes	  within	  cells,	  it	  recognizes	  DNA	  that	  has	  been	  released	  from	  microbes	  that	  have	  been	  engulfed	  and	  phagocytosed	  by	  leukocytes.	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TLR-­‐9	  activation	  stimulates	  macrophages,	  dendritic	  cells,	  B-­‐cells,	  and	  T-­‐cells	  to	  produce	  compounds	  such	  as	  proinflammatory	  cytokines	  and	  nitric	  oxide	  31.	  	  	   Cytokines	  are	  low	  molecular	  weight	  proteins	  produced	  by	  a	  majority	  of	  nucleated	  cells	  7	  responsible	  for	  mediating	  the	  host	  response	  to	  infection,	  inflammation,	  and	  trauma	  41.	  They	  can	  be	  classified	  as	  interleukins	  (IL),	  tumor	  necrosis	  factors	  (TNF),	  interferons	  (IFN),	  colony-­‐stimulating	  factors,	  and	  chemokines	  7.	  Biochemical	  interactions	  of	  cytokines	  with	  the	  host	  response	  can	  be:	  i)	  pleiotropic,	  where	  a	  particular	  cytokine	  can	  have	  many	  different	  effects;	  ii)	  redundant,	  where	  several	  cytokines	  can	  have	  the	  same	  effect;	  and	  iii)	  synergistic	  or	  antagonistic,	  where	  two	  cytokines	  can	  function	  together	  or	  in	  opposition	  of	  one	  another.	  These	  responses	  are	  dictated	  by	  timing,	  type	  of	  stimulus,	  presence	  of	  receptors,	  interaction	  with	  hormones,	  and	  many	  other	  biological	  factors	  7.	  	  	   IL-­‐1,	  IL-­‐6,	  IL-­‐8,	  and	  TNF-­‐α	  have	  been	  linked	  to	  both	  labor	  and	  PTL	  (with	  and	  without	  infection).	  The	  roles	  of	  these	  cytokines	  have	  been	  investigated	  thoroughly	  by	  several	  groups	  in	  the	  past	  decade,	  but	  our	  discussion	  will	  focus	  on	  only	  IL-­‐8	  7.	  In	  general,	  IL-­‐8	  is	  a	  chemokine	  that	  activates	  neutrophils	  and	  assists	  leukocyte	  migration	  from	  circulation	  into	  tissues	  41.	  With	  respect	  to	  preterm	  labor,	  IL-­‐8	  levels	  circulating	  in	  maternal	  blood	  are	  high	  during	  uterine	  quiescence,	  low	  during	  uterine	  activation,	  low	  during	  uterine	  stimulation,	  and	  high	  during	  involution.	  Specific	  roles	  of	  IL-­‐8	  include	  promoting	  chemotaxis,	  endothelial	  cell	  proliferation,	  reduction	  of	  focal	  adhesions	  in	  fibroblasts,	  IL-­‐1	  synthesis,	  IL-­‐6	  synthesis,	  and	  myeloperoxidase	  synthesis	  by	  leukocytes.	  Due	  to	  these	  actions,	  IL-­‐8	  may	  contribute	  to	  cervical	  remodeling	  and	  pPROM	  during	  PTL	  and	  angiogenesis	  throughout	  gestation.	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Interesting	  work	  has	  shown	  strong	  ties	  between	  elevated	  inflammatory	  cytokine	  levels	  and	  PTL.	  Dudley,	  et	  al.	  showed	  that	  blocking	  pro-­‐inflammatory	  cytokines	  (e.g.	  IL-­‐1β)	  or	  elevating	  levels	  of	  anti-­‐inflammatory	  cytokines	  (e.g.	  IL-­‐10)	  may	  suspend	  uterine	  activation.	  A	  study	  from	  the	  mid-­‐1990’s	  found	  that	  levels	  of	  IL-­‐1β,	  IL-­‐6,	  and	  TNF-­‐α	  were	  higher	  in	  laboring	  sPTL	  women	  than	  nonlaboring	  sPTL	  women.	  A	  supporting	  study	  found	  that	  TNF-­‐α	  levels	  are	  higher	  in	  PTL	  than	  TL	  7.	  	  	  
F.	  Summary	  	  	   	  	   Based	  on	  the	  information	  presented,	  it	  is	  evident	  that	  spontaneous	  preterm	  labor	  is	  a	  poorly	  understood	  disorder.	  There	  are	  many	  lines	  of	  work	  showing	  strong	  involvement	  of	  many	  genetic,	  epigenetic,	  and	  environmental	  factors	  but	  guidelines	  for	  risk	  factors,	  biomarkers,	  symptoms,	  and	  treatments	  have	  not	  yet	  been	  clearly	  defined.	  One	  conclusion	  that	  can	  be	  made	  and	  that	  has	  been	  supported	  by	  other	  researchers	  7	  is	  that	  the	  presence	  of	  bacteria	  alone	  does	  not	  fully	  explain	  sPTL.	  Given	  that	  potential	  pathways	  for	  microbial	  ascent	  from	  the	  vagina	  to	  intrauterine	  tissues	  has	  been	  outlined	  8,	  this	  thesis	  proposes	  that	  increased	  sensitivity	  of	  the	  mother	  mediated	  by	  epigenetic	  changes	  leads	  to	  early	  triggering	  of	  labor	  processes.	  	  	   Environmental	  stresses	  such	  as	  psychological	  stress	  and	  and	  poor	  nutrition,	  characterized	  by	  low	  BMI	  and	  vitamin	  and	  mineral	  deficiencies,	  are	  well	  documented	  contributors	  to	  sPTL.	  As	  previously	  mentioned,	  epigenetic	  modifications	  occur	  in	  response	  to	  changes	  in	  diet	  and	  oxidative	  stress.	  Psychological	  stress	  has	  been	  reported	  to	  increase	  oxidant	  production	  and	  result	  in	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oxidative	  damage	  42.	  DNA	  damage,	  protein	  oxidation,	  and	  lipid	  peroxidation	  (LOOH)	  are	  all	  forms	  of	  oxidative	  damage.	  Products	  of	  cell,	  DNA,	  and	  lipid	  oxidative	  damage	  (DAMPs)	  have	  been	  documented	  in	  low	  birth-­‐weight	  babies	  43.	  Thus,	  there	  is	  a	  possibility	  that	  adverse	  environmental	  stresses	  manifest	  within	  the	  body	  in	  the	  form	  of	  disorders	  such	  as	  sPTL.	  The	  activity	  of	  TET2	  in	  sPTL	  may	  explain	  how	  epigenetic	  modifications	  result	  in	  increased	  innate	  immune	  sensitivity.	  	  	   Due	  to	  its	  relatively	  recent	  discovery,	  very	  little	  is	  currently	  known	  about	  TET2.	  Its	  role	  in	  DNA	  demethylation	  makes	  it	  a	  protein	  of	  interest	  because	  Klug,	  et	  al.	  demonstrated	  its	  activation	  in	  monocytes	  as	  they	  differentiate	  into	  macrophages	  
18.	  If	  TET2	  were	  active	  in	  immune	  cells	  in	  cases	  of	  sPTL,	  it	  would	  have	  the	  opportunity	  to	  demethylate	  genes	  that	  encode	  components	  of	  innate	  immunity	  such	  as	  TLR-­‐2,	  TLR-­‐9,	  and	  IL-­‐8.	  Unpublished	  preliminary	  data	  from	  the	  Dr.	  Scott	  Walsh	  lab	  investigated	  global	  DNA	  methylation	  of	  decidual	  tissue	  of	  women	  with	  sPTL	  versus	  TL.	  Comparing	  the	  two	  groups,	  over	  2,000	  genes	  were	  found	  to	  have	  differences	  in	  methylation	  (P	  <	  0.05).	  Genes	  involved	  in	  innate	  immunity	  and	  inflammatory	  signaling	  pathways,	  such	  as	  TLRs,	  TNFα	  receptors,	  neutrophil	  cell	  adhesion	  molecules,	  and	  NF-­‐κB,	  were	  reported	  to	  be	  epigenetically	  altered	  in	  sPTL	  samples.	  More	  specifically,	  this	  study	  showed	  that	  TLR-­‐2	  and	  TLR-­‐9	  were	  significantly	  hypomethylated	  in	  decidual	  tissue	  of	  women	  with	  sPTL.	  With	  regard	  to	  TLR-­‐2,	  6	  CpG	  sites	  were	  found	  to	  be	  significantly	  hypomethylated.	  Based	  on	  their	  hypomethylation	  status,	  we	  predicted	  that	  expression	  levels	  of	  TLR-­‐2	  and	  TLR-­‐9	  would	  be	  higher	  in	  women	  with	  sPTL	  than	  in	  women	  with	  normal	  term	  labor	  or	  women	  at	  term	  not	  in	  labor.	  High	  levels	  of	  TLRs	  would	  presumably	  make	  the	  mother	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more	  sensitive	  to	  PAMPs	  and	  DAMPs	  in	  intrauterine	  tissues,	  which	  could	  originate	  from	  the	  vaginal	  microbiome.	  This	  way,	  the	  mother’s	  innate	  immunity	  could	  sense	  bacteria	  that	  are	  present	  at	  a	  subclinical	  level.	  If	  TLRs	  are	  increased,	  we	  expect	  to	  see	  increases	  in	  cytokine	  levels,	  such	  as	  IL-­‐8,	  due	  to	  the	  downstream	  signaling	  effects	  of	  PAMP	  or	  DAMP	  recognition	  by	  TLRs.	  Therefore,	  we	  have	  chosen	  to	  investigate	  levels	  of	  TLR-­‐2,	  TLR-­‐9,	  and	  IL-­‐8	  in	  sPTL	  versus	  non-­‐sPTL	  patients.	  	  	  
G.	  Purpose	  of	  investigation	  	  
Specific	  Aim	  1:	  To	  determine	  whether	  TET2	  enzyme	  is	  expressed	  in	  inflammatory	  cells	  and	  decidual	  tissue	  in	  the	  order	  TNL	  <	  TL	  <	  sPTL	  <	  iPTL	  	  
Hypothesis:	  TET2	  is	  expressed	  in	  inflammatory	  cells	  and	  decidual	  tissue	  in	  the	  order	  TNL	  <	  TL	  <	  sPTL	  <	  iPTL	  	  	  
Specific	  Aim	  2:	  To	  determine	  if	  the	  expression	  of	  TET2	  in	  decidual	  tissue	  increases	  and	  correlates	  with	  increased	  expression	  of	  TLR-­‐2	  and	  TLR-­‐9	  	  	  
Hypothesis:	  Cells	  with	  increased	  expression	  of	  TET2	  will	  also	  show	  increased	  levels	  of	  both	  TLR-­‐2	  and	  TLR-­‐9	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Specific	  Aim	  3:	  To	  determine	  if	  Lactobacillus	  rhamnosus	  (LR)	  (PAMP),	  which	  is	  commonly	  found	  in	  the	  vagina,	  and	  LOOH	  (DAMP)	  increase	  expression	  of	  TET2	  and	  activity	  of	  TLR-­‐2,	  and	  TLR-­‐9	  in	  THP-­‐1	  cells	  (human	  monocyte	  cell	  line)	  	  
Hypothesis:	  LR	  and	  LOOH	  will	  increase	  expression	  of	  TET2,	  resulting	  in	  activation	  of	  TLR-­‐2	  and	  TLR-­‐9	  	  	  
Specific	  Aim	  4:	  To	  determine	  if	  TET2	  in	  THP-­‐1	  cells	  translocates	  from	  the	  cytosol	  to	  the	  nucleus	  upon	  stimulation	  with	  phorbol	  12-­‐myristate	  13-­‐acetate	  (PMA),	  PMA+LOOH	  (DAMP),	  or	  PMA+LR	  (PAMP)	  	  
Hypothesis:	  TET2	  in	  unstimulated	  cells	  will	  be	  located	  in	  the	  cytoplasm,	  and	  upon	  stimulation	  move	  into	  the	  nucleus	  	  	  
Specific	  Aim	  5:	  To	  determine	  if	  production	  of	  IL-­‐8	  increases	  following	  treatment	  of	  THP-­‐1	  cells	  with	  PMA,	  PMA+LOOH,	  or	  PMA+LR	  	  
Hypothesis:	  Cells	  treated	  with	  PMA	  plus	  LOOH	  or	  LR	  will	  secrete	  more	  IL-­‐8	  than	  cells	  that	  are	  untreated	  or	  treated	  with	  PMA	  alone	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CHAPTER	  2:	  Materials	  and	  Methods	  	  
A.	  Immunohistochemistry	  
	   1.	  Placental	  tissue	  collection	  	  	   Whole	  placentas	  including	  fetal	  membranes	  (decidua,	  chorion	  and	  amnion)	  were	  obtained	  with	  the	  permission	  of	  patients	  from	  Virginia	  Commonwealth	  University	  Medical	  Center.	  Infected	  placentas	  were	  collected	  from	  patients	  who	  had	  given	  birth	  preterm,	  experienced	  pProm,	  and	  had	  diagnosed	  clinical	  infection.	  sPTL	  placentas	  were	  collected	  from	  pregnant	  women	  who	  gave	  birth	  prior	  to	  37	  weeks	  of	  gestation	  and	  had	  no	  clinical	  signs	  of	  infection.	  For	  the	  purposes	  of	  this	  study,	  clinical	  infection	  is	  when	  the	  mother	  experiences	  the	  following	  symptoms:	  fever	  (≥104°	  C),	  uterine	  tenderness,	  malodorous	  vaginal	  discharge,	  and	  tachycardia	  (maternal	  and	  fetal).	  TL	  placentas	  were	  collected	  from	  women	  with	  normal	  pregnancies	  who	  gave	  vaginal	  birth	  between	  37-­‐40	  weeks	  of	  gestation.	  TNL	  placentas	  were	  collected	  from	  women	  who	  underwent	  non-­‐emergency	  caesarian	  sections	  between	  37-­‐40	  weeks	  of	  gestation.	  Women	  of	  18-­‐49	  years	  of	  age	  were	  recruited	  to	  participate	  in	  the	  study.	  Smokers,	  HIV/AIDS	  patients,	  and	  drug/	  alcohol	  users	  were	  excluded	  from	  the	  study.	  Pregnancies	  with	  stillborn	  babies,	  multiple	  fetuses,	  preeclampsia,	  lupus,	  congenital	  abnormalities,	  and	  hemorrhage	  were	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excluded	  as	  well.	  Immediately	  after	  collection,	  placentas	  were	  placed	  in	  saline	  solution	  and	  refrigerated	  at	  4°	  C	  until	  ready	  for	  tissue	  preparation	  which	  was	  done	  within	  24	  hours	  of	  delivery.	  	   2.	  Placental	  tissue	  preparation	  	  	   The	  entire	  placenta	  was	  arranged	  to	  lay	  flat,	  then	  a	  rectangular	  section	  (approximately	  6	  cm	  x	  4	  cm)	  of	  tissue	  including	  amnion,	  chorion,	  and	  decidua	  was	  removed	  with	  surgical	  scissors.	  Any	  areas	  with	  tearing,	  discoloration,	  or	  any	  other	  irregularities	  were	  avoided.	  A	  roll	  with	  the	  decidua	  oriented	  towards	  the	  interior	  was	  prepared	  and	  paraffin	  embedded.	  Serial	  sections	  of	  7	  μm	  thickness	  were	  cut	  with	  a	  microtome	  (Shandon	  AS	  325).	  	  	   3.	  Immunostaining	  	  Slides	  were	  selected	  carefully	  to	  avoid	  the	  presence	  of	  tears,	  knife	  marks,	  and	  bubbles	  on	  the	  tissue	  section.	  Such	  tissue	  artifacts	  could	  inhibit	  proper	  staining	  and	  lower	  the	  image	  quality	  of	  the	  final	  stained	  section.	  Alcohol	  rehydration	  steps	  were	  performed	  by	  placing	  slides	  in	  the	  following	  separate	  containers:	  1)	  3	  Histo-­‐Clear	  (National	  Diagnostics,	  Cat.	  #	  HS-­‐200)	  (5	  min	  each),	  2)	  2	  100%	  ethanol	  (2	  min	  each),	  3)	  2	  95%	  ethanol	  (2	  min	  each),	  4)	  85%	  ethanol	  (2	  min),	  5)	  50%	  ethanol	  (2	  min),	  and	  6)	  100	  mM	  phosphate	  buffer,	  7.5	  pH	  (10	  min).	  	  Endogenous	  tissue	  peroxidase	  was	  quenched	  for	  30	  min	  with	  3%	  H2O2	  in	  methanol	  solution.	  Slides	  were	  washed	  in	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phosphate	  buffer	  for	  5	  min	  then	  in	  ddH2O	  for	  6	  min.	  Antigen	  retrieval	  was	  done	  in	  a	  pressure	  cooker	  with	  slides	  submerged	  in	  10	  mM	  citrate	  buffer	  (pH	  6.0).	  Blocking	  was	  done	  for	  45	  min	  in	  a	  humidifying	  chamber	  with	  10%	  normal	  goat	  serum	  (Invitrogen,	  Cat.	  #	  50197Z).	  To	  stain,	  100	  μL	  primary	  antibody	  (1:100	  Rabbit	  PolyAb	  Anti-­‐TET2,	  Proteintech	  Group,	  Cat.	  #	  21207-­‐1-­‐AP;	  2	  μg/mL	  Rabbit	  pAb	  to	  TLR-­‐2,	  Abcam,	  Cat.	  #	  ab24192,	  2	  μg/mL	  Rabbit	  Anti-­‐TLR-­‐9	  Antibody,	  Abcam,	  Cat.	  #	  ab37154)	  was	  applied	  to	  each	  tissue	  section	  and	  100	  μL	  negative	  control	  (Rabbit	  Primary	  Antibody	  Isotype	  Control,	  Invitrogen,	  Cat.	  #	  086199)	  was	  applied	  to	  the	  negative	  control	  tissue	  sections.	  A	  1	  hour	  incubation	  time	  (room	  temperature)	  was	  implemented	  for	  TET2,	  and	  overnight	  (4°	  C)	  for	  TLR-­‐2	  and	  TLR-­‐9.	  After	  washing,	  HRP	  polymer	  conjugate	  (Invitrogen,	  Cat.	  #	  879663)	  was	  applied	  for	  10	  min.	  DAB	  (SuperPicTureTM	  Polymer	  Detection	  Kit	  Broad	  Spectrum,	  Invitrogen,	  Cat.	  #	  879663)	  was	  applied	  for	  5	  min.	  Counterstaining	  was	  done	  with	  hematoxylin,	  then	  slides	  were	  dehyratated	  in	  the	  reverse	  order	  as	  described	  in	  the	  rehydrating	  steps.	  Tissue	  sections	  were	  preserved	  using	  a	  hard-­‐mounting	  medium	  (VectaMount	  Permanent	  Mounting	  Medium,	  Vector	  Laboratories	  Inc.,	  Cat.	  #	  H-­‐5000).	  	   4.	  Image	  analysis	  	  Representative	  images	  of	  decidua	  for	  each	  set	  of	  tissue	  sections	  (iPTL,	  sPTL,	  TL	  and	  TNL)	  were	  taken	  using	  a	  light	  microscope	  (Olympus	  BH-­‐2)	  fitted	  with	  a	  digital	  camera	  (Q-­‐Color	  5,	  Olympus,	  Cat.	  #	  32-­‐0055C-­‐157).	  All	  imaging	  and	  image	  analysis	  was	  done	  with	  cellSens	  (Olympus,	  2011	  Version	  1.4.1.).	  Relative	  differences	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in	  staining	  were	  identified	  by	  highlighting	  the	  darkest	  stained	  areas	  with	  yellow	  overlay	  using	  the	  “Measuring	  Images”	  tool	  in	  cellSens.	  Data	  were	  quantified	  and	  reported	  as	  area	  stained	  (μm2)	  and	  percent	  of	  area	  stained.	  	  	   5.	  Statistical	  analysis	  	  	  A	  parametric	  one-­‐way	  ANOVA	  (P	  <	  0.05)	  followed	  by	  a	  Newman-­‐Keuls	  post-­‐test	  were	  used	  to	  determine	  statistical	  significance	  of	  the	  means.	  GraphPad	  Prism	  4	  was	  used	  for	  statistical	  analysis	  and	  graph	  generation.	  P	  <	  0.05	  was	  considered	  statistically	  significant.	  Data	  are	  presented	  as	  mean	  ±	  SE.	  	  	  	  	  
B.	  Gene	  expression	  studies	  	   1.	  THP-­‐1	  cell	  culture	  	  THP-­‐1	  cell	  line	  (ATCC)	  was	  grown	  and	  maintained	  in	  cell	  culture	  medium.	  RPMI	  Medium	  1640	  1X	  [+]L-­‐glutamine	  (Gibco,	  Cat.	  #	  11875-­‐093)	  was	  supplemented	  with	  2.53	  g	  glucose,	  1.34	  g	  HEPES,	  57	  mL	  FBS,	  5.7	  mL	  Pen-­‐Strep,	  and	  5.7	  mL	  100	  mM	  sodium	  pyruvate,	  and	  0.05	  mM	  β-­‐mercaptoethanol	  was	  used	  to	  culture	  cells.	  It	  is	  important	  to	  note	  that	  β-­‐mercaptoethanol	  was	  added	  fresh	  before	  each	  use,	  as	  recommended	  by	  Life	  Technologies,	  due	  to	  its	  short	  half-­‐life	  and	  instability	  in	  solution.	  ATCC	  noted	  that	  the	  absence	  of	  mercaptoethanol	  or	  any	  of	  the	  other	  additives	  from	  the	  media	  “may	  affect	  recovery,	  growth	  and/or	  function	  of	  this	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strain.”	  To	  prepare	  for	  treatment,	  cells	  were	  cultured	  in	  T25	  flasks.	  The	  flasks	  were	  seeded	  at	  5	  x	  105	  cells/mL	  with	  5	  mL	  total	  volume,	  then	  incubated	  at	  37.0°	  C	  with	  5%	  CO2	  until	  ready	  for	  treatment	  (generally	  72	  hours	  after	  seeding).	  	   2.	  PMA	  treatment	  	  Phorbol	  12-­‐myristate	  13-­‐acetate	  (PMA)	  (Sigma-­‐Aldrich,	  Cat.	  #	  P8139-­‐1MG)	  was	  used	  to	  differentiate	  THP-­‐1	  monocytes	  to	  macrophages.	  During	  this	  process,	  suspended	  monocytes	  plated	  to	  the	  bottom	  of	  the	  flask	  in	  a	  single	  layer.	  PMA	  was	  added	  to	  T25	  flasks	  72	  hours	  after	  seeding.	  Subsequent	  treatments	  (e.g.	  LOOH	  and	  PAMPs)	  were	  added	  approximately	  6	  hours	  after	  the	  addition	  of	  PMA.	  When	  administering	  PMA,	  1.3	  μL	  was	  added	  to	  each	  T25	  flask	  to	  achieve	  a	  2x10-­‐8	  M	  solution.	  PMA	  required	  approximately	  4-­‐6	  hours	  to	  differentiate	  THP-­‐1	  monocytes	  into	  macrophages.	  	  	   3.	  Lactobacillus	  rhamnosus	  treatment	  	  	   Lactobacillus	  rhamnosus	  is	  a	  probiotic	  that	  has	  been	  identified	  as	  a	  microbe	  in	  the	  vaginal	  microbiome.	  It	  is	  a	  PAMP	  that	  is	  an	  agonist	  for	  TLR-­‐2.	  Heat	  killed	  L.	  
rhamnosus	  (LR)	  (Invivogen,	  Cat.	  #	  tlrl-­‐hklr)	  was	  added	  6	  hours	  after	  the	  addition	  of	  PMA.	  When	  administering	  LR,	  6.25	  μL	  (1	  x	  107	  cells/μL)	  was	  added	  to	  each	  flask	  to	  achieve	  a	  multiplicity	  of	  infection	  (MOI)	  of	  25	  (25	  bacterial	  cells	  for	  every	  1	  THP-­‐1	  cell).	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4.	  Lipid	  peroxidation	  treatment	  	  	   Lipid	  peroxidation	  (LOOH)	  treatment	  was	  administered	  approximately	  6	  hours	  after	  initial	  treatment	  of	  PMA	  after	  ensuring	  that	  most	  of	  the	  THP-­‐1	  cells	  had	  plated	  to	  the	  bottom	  of	  the	  flask.	  LOOH	  solution	  consisted	  of	  0.9	  mM	  hypoxanthine	  (HX)	  (Sigma,	  Cat.	  #	  H-­‐9377),	  50	  μM	  M	  FeSO4	  (Sigma-­‐Aldrich,	  Cat.	  #	  F8048-­‐250G),	  70	  μM	  linoleic	  acid	  (Cayman	  Chemicals,	  Cat.	  #	  90150),	  and	  0.005	  IU/mL	  xanthine	  oxidase	  (Calbiochem,	  Cat.	  #	  682151).	  Xanthine	  oxidase	  generated	  superoxide	  from	  HX	  to	  catalyze	  the	  oxidative	  stress	  reaction.	  The	  flasks	  were	  then	  incubated	  overnight	  (approximately	  18	  hours).	  	  	   5.	  5-­‐Aza-­‐2’-­‐deoxycytidine	  treatment	  	  	   5-­‐Aza-­‐2’-­‐deoxycytidine	  (5-­‐Aza)	  (Sigma-­‐Aldrich,	  Cat.	  #	  A3656-­‐5MG)	  is	  a	  drug	  that	  prevents	  methylation	  of	  newly	  synthesized	  strands	  of	  DNA	  by	  acting	  as	  an	  analogue	  of	  cytosine	  that	  is	  unable	  to	  become	  methylated	  by	  DNA	  methyltransferase.	  It	  is	  effective	  only	  during	  mitosis	  and	  functions	  to	  hypomethylate	  DNA.	  Because	  5-­‐Aza	  degrades	  quickly	  in	  solution,	  four	  2	  μL	  doses	  of	  25	  mM	  5-­‐Aza	  (final	  concentration	  10	  μM)	  were	  added	  to	  each	  flask.	  First	  dose	  was	  added	  immediately	  after	  seeding,	  second	  24	  hours	  after	  seeding,	  third	  48	  hours	  after	  seeding,	  and	  fourth	  72	  hours	  after	  seeding.	  Note	  that	  no	  PMA	  was	  added	  to	  the	  subset	  of	  5-­‐Aza	  treated	  flasks.	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6.	  THP-­‐1	  cell	  harvest	  	  THP-­‐1	  cells	  were	  harvested	  after	  overnight	  incubation	  at	  the	  end	  of	  cell	  treatment.	  Before	  harvesting,	  2	  mL	  of	  supernatant	  from	  each	  flask	  were	  collected	  and	  stored	  at	  -­‐20°	  C	  for	  analysis	  of	  IL-­‐8.	  Cells	  not	  treated	  with	  PMA	  were	  harvested	  by	  collecting	  2	  mL	  of	  the	  cell	  suspension.	  Cells	  treated	  with	  PMA	  were	  harvested	  by	  aspirating	  the	  supernatant,	  washing	  the	  cells	  twice	  with	  chilled	  1x	  PBS,	  then	  using	  a	  25	  mm	  sterile	  cell	  scraper	  to	  collect	  cells	  in	  1	  mL	  1x	  PBS.	  This	  cell	  suspension	  was	  transferred	  into	  separate	  1.5	  mL	  microcentrifuge	  tubes.	  Upon	  collection,	  tubes	  were	  placed	  on	  ice,	  then	  all	  were	  centrifuged	  for	  22	  minutes	  at	  4°	  C	  at	  2.2	  x	  g.	  	  Supernatants	  were	  removed	  from	  each	  tube	  and	  RNA	  was	  immediately	  extracted	  from	  the	  cell	  pellets.	  	  	   7.	  RNA	  extraction	  	  	   RNA	  extraction	  on	  THP-­‐1	  cells	  was	  done	  with	  Fujifilm	  Kurabo	  Quickgene	  RNA	  Cultured	  Cell	  HC	  Kit	  S	  (Cat.	  #	  RC-­‐S2)	  and	  the	  Fujifilm	  QuickGene-­‐Mini80	  apparatus.	  Immediately	  after	  removing	  the	  supernatants	  from	  the	  cell	  pellets,	  lysis	  buffer	  was	  added	  to	  each	  tube	  to	  lyse	  the	  cells.	  Solubilization	  buffer	  and	  ethanol	  were	  added	  to	  solubilize	  and	  keep	  the	  cell	  components	  suspended	  in	  solution.	  The	  lysate	  was	  transferred	  to	  the	  QuickGene	  cartridge	  for	  isolation	  of	  RNA.	  Vacuum	  filtration	  and	  washing	  with	  wash	  buffer	  was	  done	  to	  filter	  out	  unwanted	  cellular	  components,	  so	  that	  only	  RNA	  and	  DNA	  were	  left	  on	  the	  cartridge	  filter	  paper.	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DNase	  was	  added	  to	  digest	  the	  DNA,	  then	  vacuumed	  to	  rid	  the	  cartridge	  filter	  paper	  of	  unwanted	  DNA	  segments.	  After	  washing	  two	  more	  times,	  elution	  buffer	  was	  applied	  to	  the	  cartridge	  so	  that	  RNA	  in	  the	  elution	  buffer	  could	  be	  vacuumed	  into	  the	  final	  tube	  for	  the	  RNA.	  The	  concentration	  and	  purity	  of	  RNA	  were	  immediately	  determined	  using	  a	  Nanodrop	  2000	  spectrophotometer	  (Thermo	  Scientific)	  and	  the	  Nanodrop	  2000	  program.	  RNA	  concentration	  (ng/μL)	  and	  260/280	  (measure	  of	  purity)	  were	  recorded.	  A	  260/280	  value	  between	  2.00	  and	  2.20	  was	  regarded	  as	  highly	  pure	  and	  acceptable.	  	   	  8.	  cDNA	  conversion	  	   	  	   RNA	  (1000	  ng)	  was	  converted	  to	  cDNA	  using	  iScript	  Reverse	  Transcription	  Supermix	  for	  RT-­‐qPCR	  (BioRad,	  Cat.	  #	  170-­‐8840)	  to	  yield	  1000	  ng	  of	  cDNA.	  PCR	  tubes	  with	  a	  mixture	  of	  5x	  iScript	  RT	  supermix	  (iScript	  MMLV-­‐RT	  [RNaseH+],	  RNase	  inhibitor,	  dNTPs,	  oligo	  (dT),	  random	  primers,	  buffer,	  MgCl2,	  and	  stabilizers),	  nuclease-­‐free	  water,	  and	  RNA	  extract	  were	  incubated	  in	  a	  thermal	  cycler	  which	  facilitated	  priming	  the	  RNA	  for	  5	  minutes	  at	  25°	  C,	  reverse	  transcription	  for	  30	  minutes	  at	  42°	  C,	  and	  RT	  inactivation	  for	  5	  minutes	  at	  85°C.	  Nuclease-­‐free	  water	  was	  used	  to	  dilute	  the	  RNA	  extract	  so	  that	  the	  final	  yield	  of	  cDNA	  was	  1000	  ng/20	  μL.	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9.	  Quantitative	  Real	  Time	  Polymerase	  Chain	  Reaction	  (qRT-­‐PCR)	  	  	   cDNA	  concentration	  (1000	  ng/20	  μL	  =	  50	  ng/μL)	  was	  diluted	  to	  8	  ng/μL	  with	  nuclease-­‐free	  water.	  For	  qRT-­‐PCR,	  12.5	  μL	  RT2	  SYBR	  Green	  RoxTM	  qPCR	  Mastermix	  (Qiagen,	  Cat.	  #	  330522),	  10.5	  μL	  nuclease-­‐free	  water,	  and	  1	  μL	  cDNA	  (8	  ng/μL)	  were	  added	  to	  each	  well	  in	  a	  PCR	  reaction	  plate.	  Next,	  1	  μL	  of	  primer	  was	  added	  to	  each	  well	  individually.	  The	  housekeeping	  gene	  was	  GAPDH	  (Integrated	  DNA	  Technologies	  Inc.).	  Other	  primers	  used	  were	  TET2	  (SA	  Biosciences,	  Cat.	  #	  PPH17943E-­‐200),	  TLR-­‐9	  (Integrated	  DNA	  Technologies	  Inc.),	  TLR-­‐2	  (Integrated	  DNA	  Technologies	  Inc.),	  and	  IL-­‐8	  (SA	  Biosciences,	  Cat.	  #	  PPH00568A-­‐200).	  qRT-­‐PCR	  was	  conducted	  with	  Realplex	  Mastercycler	  epgradientS	  (Eppendorf).	  The	  cycling	  protocol	  consisted	  of	  2	  minutes	  of	  initial	  denaturing	  at	  95°	  C,	  15	  seconds	  of	  denaturing	  at	  95°	  C,	  15	  seconds	  of	  polymerization	  at	  55°	  C,	  and	  20	  seconds	  of	  data	  reading	  at	  68°	  C.	  All	  steps	  except	  initial	  denaturing	  underwent	  the	  cycle	  40	  times.	  The	  threshold	  cycle	  (Ct)	  values	  and	  other	  relevant	  data	  were	  recorded.	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Table	  1:	  Sequences	  for	  qRT-­‐PCR	  primers	  	  	  	  Gene	  Name	   	   	   Sequence	  (5’-­‐3’)	  GAPDH	   	   	   F:	  5’-­‐GAT	  TCC	  ACC	  CAT	  GGC	  AAA	  TT-­‐3’	  	   	   	   	   R:	  5’-­‐AGA	  TGG	  TGA	  TGG	  GAT	  TTC	  CAT-­‐3’	  	  TET2	   	   	   	   N/A,	  commercially	  attained	  	  	  TLR-­‐2	   	   	   	   F:	  5’-­‐CCT	  GGC	  CCT	  CTC	  TAC	  AAA	  CTT-­‐3’	  	   	   	   	   R:	  5’-­‐ACT	  GTG	  TAT	  TCG	  TGT	  GCT	  GGA	  TA-­‐3’	  	  TLR-­‐9	   	   	   	   F:	  5’-­‐CTG	  CCA	  CAT	  GAC	  CAT	  CGA	  G-­‐3’	  	   	   	   	   R:	  5’-­‐GGA	  CAG	  GGA	  TAT	  GAG	  GGA	  TTT-­‐3’	  	  IL-­‐8	   	   	   	   N/A,	  commercially	  attained	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10.	  Analysis	  of	  Results	  	  An	  Excel	  spreadsheet	  was	  set	  up	  to	  process	  the	  raw	  Ct	  values	  and	  calculate	  changes	  in	  gene	  expression	  of	  TET2,	  TLR-­‐9,	  TLR-­‐2,	  and	  IL-­‐8	  compared	  to	  the	  housekeeping	  gene,	  GAPDH.	  These	  results	  were	  then	  arranged	  into	  a	  bar	  graph	  with	  the	  aid	  of	  GraphPad	  Prism	  4	  software.	  A	  parametric	  one-­‐way	  ANOVA	  (P	  <	  0.05)	  followed	  by	  a	  Newman-­‐Keuls	  post-­‐test	  were	  used	  to	  determine	  statistical	  significance	  of	  the	  means.	  IL-­‐8	  raw	  data	  from	  Fig.	  7D	  was	  transformed	  to	  Y=Log(Y)	  because	  treatment	  results	  increased	  logarithmically	  and	  variance	  of	  the	  data	  was	  large.	  Data	  from	  Fig.	  8D	  was	  analyzed	  using	  a	  non-­‐parametric	  Kruskal-­‐Wallis	  test	  followed	  by	  a	  Dunnett’s	  multiple	  comparison	  test.	  P	  <	  0.05	  was	  considered	  statistically	  significant.	  Data	  are	  presented	  as	  mean	  ±	  SE.	  	  	  	  
C.	  Fluorescence	  immunohistochemistry	  	  	  	   1.	  Staining	  	  	   Immunostaining	  was	  done	  on	  THP-­‐1	  cells	  that	  were	  treated	  with	  i)	  PMA,	  ii)	  PMA+LOOH,	  iii)	  PMA+LR.	  Control	  cells	  were	  untreated	  and	  remained	  in	  suspension.	  Two-­‐chambered	  slides	  were	  seeded	  with	  5	  x	  105	  cells/mL.	  Control	  cells	  were	  spun	  down,	  resuspended	  in	  a	  smaller	  volume	  of	  media,	  then	  allowed	  to	  air-­‐dry	  but	  still	  remain	  moist	  (~1	  hr).	  After	  24	  hours	  of	  incubation,	  both	  control	  and	  treated	  cells	  were	  fixed	  with	  4%	  formalin.	  Blocking	  was	  done	  at	  room	  temperature	  for	  60	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minutes	  with	  a	  solution	  of	  10%	  goat	  serum,	  3%	  BSA,	  and	  0.2%	  Triton-­‐X.	  Cells	  were	  incubated	  overnight	  with	  primary	  antibody	  (PolyAb	  Anti-­‐TET2,	  Proteintech	  Group,	  Cat.	  #	  21207-­‐1-­‐AP)	  diluted	  1/500	  in	  10%	  goat	  serum.	  Secondary	  antibody	  (Alexa	  Fluor	  488	  Donkey	  Anti-­‐Rabbit	  IgG	  H+L	  Antibody,	  Life	  Technologies,	  Cat.	  #	  A-­‐21206)	  was	  diluted	  1/5000	  and	  incubated	  in	  darkness	  for	  1-­‐2	  hours.	  Mounting	  medium	  for	  fluorescence	  with	  DAPI	  (Vectashield,	  Vector	  Laboratories	  Inc.)	  was	  used	  to	  preserve	  the	  slides.	  	  	  	   2.	  Image	  analysis	  	  	   Image	  analysis	  was	  done	  using	  a	  confocal	  microscope	  (Virginia	  Commonwealth	  University	  Microscopy	  Core,	  Leica	  TCS-­‐SP2	  AOBS,	  inverted).	  Images	  were	  processed	  using	  Preview	  (Apple,	  Inc.).	  	  	  
D.	  IL-­‐8	  enzyme-­‐linked	  immunoabsorbent	  assay	  (ELISA)	  	  	   1.	  Plate	  preparation	  	   	  	   Capture	  antibody	  (Anti-­‐human	  IL-­‐8	  monoclonal	  antibody,	  R&D	  Systems,	  Cat.	  #	  MAB208,	  4	  μg/mL)	  was	  applied	  to	  a	  96-­‐well	  plate	  (Corning	  Incorporated,	  Costar,	  Cat.	  #	  3590)	  and	  incubated	  overnight.	  Wells	  were	  blocked	  with	  1%	  BSA,	  5%	  sucrose,	  0.05%	  NaN3,	  and	  PBS	  for	  1	  hour.	  Standards	  were	  diluted	  in	  FBS-­‐free	  RPMI	  complete	  media	  and	  allowed	  to	  incubate	  in	  wells	  for	  2	  hours.	  Control	  samples	  were	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not	  diluted.	  Media	  from	  PMA,	  PMA+LOOH,	  LOOH,	  5-­‐Aza,	  and	  PMA+LR	  treated	  flasks	  were	  diluted	  1:20	  for	  assay.	  Detection	  antibody	  (Biotinylated	  Anti-­‐human	  IL-­‐8	  Antibody,	  R&D	  Systems	  Cat.	  #	  BAF208,	  20	  ng/mL)	  was	  added	  and	  incubated	  for	  2	  hours.	  Streptavidin	  HRP	  (1/8000,	  diluted	  in	  diluent	  solution	  –	  20	  mM	  Trizma	  base,	  150	  mM	  NaCl,	  0.1%	  BSA,	  and	  0.05%	  Tween	  20)	  was	  incubated	  for	  20	  minutes.	  Substrate	  solution	  was	  incubated	  for	  30	  min.	  Finally	  stop	  solution	  (1	  M	  H2SO4)	  was	  added	  to	  each	  well.	  	  	   2.	  Results	  analysis	  	  The	  ELISA	  plate	  was	  read	  using	  a	  spectrophometer	  (FLUOstar	  OPTIMA,	  BMG	  Labtech)	  at	  450	  nm.	  Standard	  curve	  was	  analyzed	  using	  a	  4-­‐parameter	  fit	  using	  raw	  averages	  based	  on	  results	  from	  standard	  dilutions	  in	  duplicate.	  An	  r2	  value	  above	  0.99	  was	  considered	  accurate	  and	  precise.	  Results	  were	  arranged	  into	  a	  bar	  graph	  using	  GraphPad	  Prism	  4	  Software.	  A	  one-­‐way	  ANOVA	  test	  and	  a	  Newman-­‐Keuls	  post	  test	  were	  done	  to	  determine	  significance	  of	  the	  data.	  P	  <	  0.05	  was	  considered	  statistically	  significant.	  Data	  are	  presented	  as	  mean	  ±	  SE.	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  






CHAPTER	  3:	  Results	  
	  
A.	  Immunohistochemistry	  	   The	  intensity	  and	  area	  of	  decidual	  tissue	  staining	  was	  assessed	  using	  cellSens	  software	  and	  visualized	  using	  yellow	  highlighting.	  For	  the	  most	  part,	  representative	  images	  (Fig.	  2)	  of	  decidua	  showed	  a	  concentration	  of	  TET2	  and	  TLR	  staining	  in	  the	  boundary	  facing	  the	  chorion.	  Intensely	  stained	  cell	  types	  included	  mostly	  immune	  cells	  (small,	  dark	  and	  round,	  many	  with	  polymorphonucelar	  nucleus)	  and	  some	  decidual	  cells	  (large	  nucleus	  with	  diffuse	  cytoplasm).	  Light	  background	  staining	  was	  observed	  mostly	  in	  TLR-­‐2	  stained	  sections,	  but	  was	  present	  for	  TET2	  and	  TLR-­‐9	  stained	  ones	  as	  well.	  Quantification	  of	  staining	  indicated	  that	  TET2	  expression	  (Fig.	  2,	  top	  row)	  increased	  in	  the	  order	  TNL	  (n	  =	  5)	  <	  TL	  (n	  =	  6)	  <	  sPTL	  (n	  =	  4)	  <	  iPTL	  (n	  =	  3).	  Images	  of	  TLR-­‐9	  staining	  (TNL	  n	  =	  5,	  TL	  n	  =	  5,	  sPTL	  n	  =	  3,	  iPTL	  n	  =	  3)	  and	  TLR-­‐2	  staining	  (TNL	  n	  =	  6,	  TL	  n	  =	  4,	  sPTL	  n	  =	  4,	  iPTL	  n	  =	  2)	  demonstrated	  that	  they	  followed	  the	  same	  expression	  pattern	  as	  TET2	  (TNL	  <	  TL	  <	  sPTL	  <	  iPTL)	  (Fig.	  2	  middle	  and	  bottom	  rows,	  respectively).	  Immunostaining	  for	  TET2	  for	  area	  stained	  demonstrated	  (Fig.	  3A)	  increased	  expression	  in	  the	  order	  TNL	  (273	  μm2	  ±	  34)	  <	  TL	  (950	  μm2	  ±	  92)	  <	  sPTL	  (2754	  μm2	  ±	  703)	  <	  iPTL	  (6937	  μm2	  ±	  324).	  Percentage	  of	  decidual	  tissue	  area	  that	  expressed	  TET2	  (Fig.	  3B)	  also	  followed	  the	  order	  of	  TNL	  (0.8	  ±	  0.1)	  <	  TL	  (2.7	  ±	  0.3)	  <	  sPTL	  (7.9	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±	  1.9)	  <	  iPTL	  (18.4	  ±	  1.6).	  Expression	  levels	  of	  TET2	  in	  iPTL	  (P	  <	  0.001)	  and	  sPTL	  (P	  <	  0.001)	  were	  significantly	  higher	  than	  TNL	  and	  TL.	  There	  was	  no	  statistical	  difference	  between	  TNL	  and	  TL	  (P	  >	  0.05).	  	  TLR-­‐2	  immunostaining	  results	  showed	  a	  similar	  pattern	  for	  area	  stained	  (Fig.	  4A)	  where,	  expression	  increased	  in	  the	  order	  TNL	  (244	  μm2	  ±	  70)	  <	  TL	  (653	  μm2	  ±	  74)	  <	  sPTL	  (2717	  μm2	  ±	  402)	  <	  iPTL	  (5544	  μm2	  ±	  671).	  Percentage	  of	  decidual	  tissue	  that	  expressed	  TLR-­‐2	  (Fig.	  4B)	  also	  increased	  in	  the	  order	  of	  TNL	  (0.7	  ±	  0.2)	  <	  TL	  (1.8	  ±	  0.2)	  <	  sPTL	  (7.7	  ±	  1.1)	  <	  iPTL	  (15.6	  ±	  1.9).	  Expression	  levels	  of	  TLR-­‐2	  in	  iPTL	  (P	  <	  0.001)	  and	  sPTL	  (P	  <	  0.001)	  were	  significantly	  greater	  than	  TNL	  and	  TL.	  There	  was	  no	  statistical	  difference	  between	  TNL	  and	  TL	  (P	  >	  0.05).	  	  TLR-­‐9	  immunostaining	  results	  (Fig.	  5A)	  were	  similar,	  where	  area	  stained	  increased	  in	  the	  order	  of	  TNL	  (1103	  μm2	  ±	  207)	  <	  TL	  (2671	  μm2	  ±	  595)	  <	  sPTL	  (6064	  μm2	  ±	  1048)	  <	  iPTL	  (14142	  μm2	  ±	  301).	  Percentage	  of	  decidual	  tissue	  that	  expressed	  TLR-­‐9	  (Fig.	  5B)	  also	  increased	  in	  the	  order	  of	  TNL	  (3.2	  ±	  0.7)	  <	  TL	  (7.6	  ±	  1.8)	  <	  sPTL	  (17	  ±	  2.5)	  <	  iPTL	  (40	  ±	  0.9).	  Expression	  levels	  of	  TLR-­‐9	  in	  iPTL	  (P	  <	  0.001),	  sPTL	  (P	  <	  0.001),	  and	  TL	  (P	  <	  0.05)	  were	  significantly	  greater	  than	  TNL,	  and	  iPTL	  and	  sPTL	  were	  significantly	  greater	  than	  TL.	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Figure	  2:	  Representative	  Images	  of	  immunohistochemistry	  results	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Figure	  3:	  Area	  (μm2)	  and	  percent	  area	  of	  TET2	  stained	  in	  human	  decidual	  
tissue	  (***	  P	  <	  0.001)	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Figure	  4:	  Area	  (μm2)	  and	  percent	  area	  of	  TLR-­‐2	  stained	  in	  human	  decidual	  
tissue	  (***	  P	  <	  0.001)	  	  
	  

























Figure	  5:	  Area	  (μm2)	  and	  percent	  area	  of	  TLR-­‐9	  stained	  in	  human	  decidual	  
tissue	  (***	  P	  <	  0.001,	  *	  P	  <	  0.05)	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B.	  Gene	  expression	  studies	  
	  
	   Figure	  6	  summarizes	  data	  from	  THP-­‐1	  monocytes	  treated	  with	  5-­‐Aza	  (TET2	  n	  =	  7,	  TLR-­‐2	  n	  =	  7,	  TLR-­‐9	  n	  =	  7,	  IL-­‐8	  n	  =	  7).	  Gene	  expression	  of	  TET2	  significantly	  increased	  by	  2.6	  fold	  ±	  0.5	  (P	  <	  0.001)	  compared	  to	  control	  cells	  (1	  fold	  ±	  0.01,	  n	  =	  12)	  (Fig.	  6A).	  Expression	  of	  TLR-­‐2	  significantly	  increased	  by	  2.0	  fold	  ±	  0.1	  (P	  <	  0.001)	  compared	  to	  control	  cells	  (1	  fold	  ±	  0.02,	  n	  =	  8)	  (Fig.	  6B).	  Expression	  of	  TLR-­‐9	  significantly	  increased	  by	  6.2	  fold	  ±	  0.9	  (P	  <	  0.001)	  compared	  to	  control	  cells	  (1	  fold	  ±	  0.01,	  n	  =	  10)	  (Fig.	  6C).	  Gene	  expression	  of	  IL-­‐8	  significantly	  increased	  by	  7.8	  fold	  ±	  2.4	  (P	  <	  0.001)	  compared	  to	  control	  cells	  (1	  fold	  ±	  0.01,	  n	  =	  12)	  (Fig.	  6D).	  	  	   Figure	  7A	  summarizes	  data	  for	  the	  gene	  expression	  of	  TET2	  in	  THP-­‐1	  monocytes	  (control	  n	  =	  12,	  LOOH	  n	  =	  3)	  and	  macrophages	  (PMA	  n	  =	  8,	  PMA+LOOH	  n	  =	  8).	  Expression	  of	  TET2	  significantly	  increased	  by	  2.9	  fold	  ±	  0.5	  (P	  <	  0.01)	  in	  PMA	  treated	  cells	  and	  by	  3.4	  ±	  0.5	  (P	  <	  0.001)	  in	  PMA+LOOH	  treated	  cells	  compared	  to	  control	  group	  (1	  fold	  ±	  0.01).	  TET2	  gene	  expression	  in	  LOOH	  treated	  cells	  (1.6	  fold	  ±	  0.4)	  was	  not	  statistically	  different	  than	  control	  cells.	  	  Figure	  7B	  summarizes	  data	  for	  the	  gene	  expression	  of	  TLR-­‐2	  in	  THP-­‐1	  monocytes	  (control	  n	  =	  9,	  LOOH	  n	  =	  3)	  and	  macrophages	  (PMA	  n	  =	  8,	  PMA+LOOH	  n	  =	  6).	  Gene	  expression	  of	  TLR-­‐2	  significantly	  increased	  by	  5.1	  fold	  ±	  0.6	  (P	  <	  0.001)	  in	  PMA	  treated	  cells,	  by	  6.7	  fold	  ±	  0.5	  (P	  <	  0.001)	  in	  PMA+LOOH	  treated	  cells,	  and	  3.0	  fold	  ±	  0.1	  (P	  <	  0.01)	  in	  LOOH	  treated	  cells	  compared	  to	  control	  group	  (1	  fold	  ±	  0.02).	  	  Figure	  7C	  summarizes	  data	  for	  the	  gene	  expression	  of	  TLR-­‐9	  in	  THP-­‐1	  monocytes	  (control	  n	  =	  12,	  LOOH	  n	  =	  12)	  and	  macrophages	  (PMA	  n	  =	  8,	  PMA+LOOH	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n	  =	  8).	  Gene	  expression	  of	  TLR-­‐9	  significantly	  increased	  by	  4.0	  fold	  ±	  0.6	  (P	  <	  0.001)	  in	  PMA	  treated	  cells	  and	  by	  3.4	  ±	  0.3	  (P	  <	  0.001)	  in	  PMA+LOOH	  treated	  cells	  compared	  to	  control	  group	  (1	  fold	  ±	  0.01).	  TLR-­‐9	  gene	  expression	  in	  LOOH	  treated	  cells	  increased	  by	  1.1	  fold	  ±	  0.03	  which	  was	  not	  significantly	  higher	  than	  its	  expression	  in	  control	  cells	  (1	  fold	  ±	  0.01).	  Figure	  7D	  summarizes	  data	  for	  the	  gene	  expression	  of	  IL-­‐8	  in	  THP-­‐1	  monocytes	  (control	  n	  =	  12,	  LOOH	  n	  =	  3)	  and	  macrophages	  (PMA	  n	  =	  8,	  PMA+LOOH	  n	  =	  7).	  Gene	  expression	  of	  IL-­‐8	  significantly	  increased	  by	  1650	  fold	  ±	  457	  (P	  <	  0.001)	  in	  PMA+LOOH	  treated	  cells	  compared	  to	  control	  group	  (1	  fold	  ±	  0.1).	  IL-­‐8	  gene	  expression	  in	  PMA	  treated	  cells	  increased	  by	  107	  fold	  ±	  33	  (P	  <	  0.001)	  and	  by	  172	  fold	  ±	  24	  (P	  <	  0.001)	  in	  LOOH	  treated	  cells,	  both	  of	  which	  were	  significantly	  higher	  than	  the	  control	  group.	  	  
	   Figure	  8A	  summarizes	  data	  for	  the	  gene	  expression	  of	  TET2	  in	  control	  (n	  =	  12),	  PMA	  (n	  =	  8),	  and	  PMA+LR	  (n	  =	  4)	  treated	  cells.	  PMA	  treated	  cells	  increased	  gene	  expression	  of	  TET2	  by	  2.9	  fold	  ±	  0.5	  and	  PMA+LR	  increased	  it	  by	  2.0	  fold	  ±	  0.1	  (P	  <	  0.001	  and	  P	  <	  0.05,	  respectively)	  compared	  to	  control	  cells	  (1	  fold	  ±	  0.01).	  	   Figure	  8B	  summarizes	  data	  for	  the	  gene	  expression	  of	  TLR-­‐2	  in	  control	  (n	  =	  9),	  PMA	  (n	  =	  9),	  and	  PMA+LR	  (n	  =	  4)	  treated	  cells.	  PMA	  treated	  cells	  increased	  gene	  expression	  of	  TLR-­‐2	  by	  5.1	  fold	  ±	  0.6	  and	  PMA+LR	  treatment	  increased	  it	  by	  4.5	  fold	  ±	  0.5	  (P	  <	  0.001	  and	  P	  <	  0.001,	  respectively)	  compared	  to	  control	  group	  (1	  fold	  ±	  0.02).	  	  	   Figure	  8C	  summarizes	  data	  for	  the	  gene	  expression	  of	  TLR-­‐9	  in	  control	  (n	  =	  10),	  PMA	  (n	  =	  8),	  and	  PMA+LR	  (n	  =	  4)	  treated	  cells.	  PMA	  treated	  cells	  increased	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Figure	  6:	  Gene	  expression	  of	  TET2,	  TLR-­‐2,	  TLR-­‐9,	  and	  IL-­‐8	  in	  5-­‐aza	  treated	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Figure	  7:	  Gene	  expression	  of	  TET2,	  TLR-­‐2,	  TLR-­‐9,	  and	  IL-­‐8	  in	  LOOH	  (DAMP)	  	  
treated	  THP-­‐1	  monocytes	  and	  macrophages	  (**	  P	  <	  0.01,	  ***	  P	  <	  0.001)	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Figure	  8:	  Gene	  expression	  of	  TET2,	  TLR-­‐2,	  TLR-­‐9,	  and	  IL-­‐8	  in	  L.	  rhamnosus	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C.	  Fluorescence	  immunohistochemistry	  
	  
	   Qualitative	  visual	  analysis	  of	  TET2	  translocation	  representative	  images	  demonstrates	  its	  movement	  from	  the	  cytosol	  to	  the	  nucleus	  upon	  stimulation	  with	  PMA,	  LOOH	  (DAMP),	  and	  L.	  rhamnosus	  (PAMP).	  In	  control	  cells	  (Fig.	  9,	  first	  row),	  TET2	  was	  detected	  primarily	  in	  the	  cytosol	  but	  some	  was	  present	  in	  the	  nucleus	  as	  well.	  The	  nucleus	  was	  identified	  by	  DAPI,	  which	  stains	  DNA	  blue	  (Fig.	  9A).	  TET2	  was	  identified	  in	  green	  with	  GFP	  (Fig.	  9B).	  Image	  representing	  the	  overlap	  of	  DAPI+TET2	  (Fig.	  9C,	  first	  row)	  visually	  showed	  the	  heavy	  presence	  of	  TET2	  in	  the	  cytosol.	  In	  PMA	  treated	  cells,	  TET2	  was	  present	  mostly	  within	  the	  nucleus	  (Fig.	  9,	  second	  row).	  Image	  of	  TET2	  alone	  (Fig.	  9B,	  second	  row)	  showed	  a	  ring	  of	  TET2	  concentrated	  around	  the	  nucleus	  but	  the	  rest	  of	  the	  cytosol	  was	  relatively	  free	  of	  the	  protein.	  Image	  of	  DAPI+TET2	  (Fig.	  9C,	  second	  row)	  showed	  a	  heavy	  presence	  of	  DNA	  and	  TET2	  in	  the	  same	  location.	  In	  PMA+LOOH	  treated	  cells,	  image	  of	  TET2	  alone	  (Fig.	  9B,	  third	  row)	  showed	  translocation	  of	  TET2	  from	  the	  cytosol	  to	  the	  nucleus	  when	  compared	  to	  control	  cells.	  The	  ring	  of	  TET2	  around	  the	  nucleus	  was	  not	  as	  heavy	  as	  in	  PMA	  treated	  cells.	  TET2	  in	  PMA+LR	  treated	  cells	  (Fig.	  9,	  fourth	  row)	  was	  concentrated	  primarily	  in	  the	  nucleus	  with	  low	  levels	  in	  the	  cytosol.	  	  	  	  




Figure	  9:	  Representative	  Confocal	  images	  of	  fluorescent	  detection	  of	  TET2	  in	  
THP-­‐1	  cells	  
	  Treated	  THP-­‐1	  cells	  were	  stained	  for	  TET2	  with	  anti-­‐TET2	  polyclonal	  antibody	  and	  secondary	  GFP	  antibody.	  A)	  DAPI	  stain	  for	  nuclear	  DNA.	  B)	  GFP	  stain	  for	  TET2.	  C)	  DAPI	  overlaid	  with	  TET2.	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D.	  IL-­‐8	  enzyme-­‐linked	  immunoabsorbant	  assay	  (ELISA)	  
	  














Figure	  10:	  IL-­‐8	  secreted	  by	  THP-­‐1	  cells	  in	  response	  to	  various	  treatments	  	  (*	  P	  <	  0.05,	  ***	  P	  <	  0.001)	  	  	  	  	  	  	  	  






















CHAPTER	  4:	  Discussion	  
	  
	  
A.	  TET2,	  TLR-­‐2,	  and	  TLR-­‐9	  expression	  levels	  in	  human	  decidua	  	  	  	   TET2	  is	  a	  primary	  effector	  of	  DNA	  demethylation	  24,	  but	  its	  presence	  and	  function	  in	  intrauterine	  tissue	  as	  it	  relates	  to	  perinatal	  outcomes	  has	  not	  been	  investigated.	  We	  found	  that	  constituent	  immune	  cells	  of	  decidual	  tissue	  express	  TET2	  in	  a	  positive	  correlation	  with	  increasing	  gestational	  dysfunction.	  Spontaneous	  preterm	  labor	  showed	  greater	  staining	  for	  TET2	  than	  term	  labor,	  with	  infected	  preterm	  labor	  showing	  an	  even	  further	  increase.	  Additionally,	  IHC	  staining	  for	  TLR-­‐2	  and	  TLR-­‐9	  followed	  the	  same	  pattern	  as	  TET2.	  A	  global	  methylation	  analysis	  of	  decidual	  tissue	  from	  sPTL	  and	  TL	  patients	  indicated	  the	  gene	  loci	  for	  TLR-­‐2	  and	  TLR-­‐9	  were	  significantly	  hypomethylated	  in	  sPTL	  compared	  to	  TL,	  which	  supports	  the	  notion	  that	  increased	  TET2	  expression	  might	  be	  responsible.	  The	  mechanism	  by	  which	  TET2	  specifically	  targets	  such	  genes	  is	  currently	  unknown,	  but	  future	  experiments	  may	  elucidate	  that	  mechanism	  as	  well	  as	  additional	  genes	  that	  are	  affected	  by	  TET2	  in	  PTL.	  	  The	  correlation	  of	  TET2	  expression	  with	  TLR-­‐2	  and	  TLR-­‐9	  in	  decidual	  tissues	  suggests	  TET2	  demethylation	  may	  be	  responsible	  for	  the	  upregulation	  of	  these	  TLRs.	  The	  high	  levels	  of	  TET2	  associated	  with	  iPTL	  and	  sPTL	  could	  be	  responsible	  for	  the	  greater	  transcription	  of	  TLR-­‐2	  and	  TLR-­‐9	  genes,	  thus,	  generating	  more	  TLR	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protein;	  whereas,	  the	  lower	  TET2	  expression	  associated	  with	  TNL	  and	  TL	  could	  be	  responsible	  for	  the	  lesser	  TLR	  protein.	  	  
B.	  TET2,	  TLR-­‐2,	  TLR-­‐9,	  and	  IL-­‐8	  expression	  levels	  in	  stimulated	  THP-­‐1	  cells	  	  	   Many	  recent	  studies	  on	  PTL	  have	  focused	  on	  describing	  the	  role	  of	  specific	  bacterial	  strains	  in	  the	  development	  of	  both	  iPTL	  and	  sPTL,	  but	  	  it	  is	  equally	  necessary	  to	  investigate	  host-­‐microbe	  interactions.	  Few	  studies	  have	  focused	  on	  the	  influence	  of	  epigenetic	  modifications	  on	  PTL,	  which	  have	  been	  shown	  to	  alter	  cellular	  behavior	  in	  response	  to	  environmental	  cues	  20.	  In-­‐depth	  evaluations	  by	  different	  investigators	  on	  the	  causes	  of	  PTL	  agree	  that	  many	  mothers	  suffering	  PTL	  also	  face	  environmental	  stresses	  throughout	  gestation.	  Such	  stresses	  include	  poor	  diet	  (e.g.	  vitamin	  and	  mineral	  deficiency	  and	  low	  BMI)	  and	  psychological	  stresses	  (e.g.	  socioeconomic	  circumstances)	  1,	  3.	  TET2	  may	  serve	  as	  the	  link	  between	  these	  two	  systems.	  	  Our	  preliminary	  investigation	  showed	  that	  genes	  encoding	  TET2,	  TLR-­‐2,	  TLR-­‐9,	  and	  IL-­‐8	  are	  all	  transcriptionally	  regulated	  by	  epigenetic	  modifications.	  Compared	  to	  THP-­‐1	  monocytes	  that	  retained	  normal	  methylation	  patterns	  (control	  group),	  cells	  that	  experienced	  global	  DNA	  demethylation	  (5-­‐aza	  group)	  showed	  significantly	  increased	  gene	  expression	  of	  TET2,	  TLR-­‐2,	  TLR-­‐9,	  and	  IL-­‐8.	  This	  demonstrates	  that	  epigenetic	  regulation	  does	  have	  an	  effect	  on	  monocytes.	  	  In	  Figure	  9,	  THP-­‐1	  cells	  differentiated	  to	  macrophages	  by	  PMA	  treatment	  exhibited	  heightened	  production	  of	  TET2	  mRNA	  transcripts,	  which	  suggests	  that	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TET2	  is	  downregulated	  in	  monocytes	  but	  upregulated	  in	  macrophages.	  Higher	  expression	  of	  TET2	  in	  PMA+LOOH	  versus	  PMA	  macrophages	  suggests	  that,	  in	  vivo,	  TET2	  expression	  may	  be	  elevated	  in	  tissues	  exposed	  to	  environmental	  stressors.	  Lipid	  peroxidation	  is	  one	  type	  of	  oxidative	  stress	  that	  results	  in	  DNA	  and	  cell	  membrane	  damage	  43.	  Psychological	  stresses	  have	  been	  linked	  to	  increased	  oxidative	  stress	  42.	  Although	  TET2	  expression	  in	  LOOH	  treated	  monocytes	  did	  not	  increase	  significantly	  compared	  to	  untreated	  monocytes,	  it	  is	  worthy	  to	  note	  that	  average	  fold	  change	  was	  1.6	  fold	  ±0.4	  compared	  to	  1.0	  fold	  ±0.01.	  Increasing	  the	  sample	  size,	  which	  was	  only	  3,	  may	  show	  this	  difference	  to	  be	  significant.	  	  Gene	  expression	  patterns	  of	  TLR-­‐2	  and	  IL-­‐8	  follow	  a	  similar	  pattern	  to	  TET2	  supporting	  a	  positive	  correlation	  between	  TET2	  and	  genes	  associated	  with	  innate	  immunity.	  The	  qRT-­‐PCR	  analysis	  for	  TLR-­‐9	  for	  the	  same	  THP-­‐1	  treatments	  yielded	  slightly	  different	  results	  in	  that	  TLR-­‐9	  expression	  was	  higher	  in	  PMA	  than	  PMA+LOOH.	  This	  may	  indicate	  that	  PMA	  increases	  expression	  of	  TET2	  as	  well	  as	  TLRs,	  but	  addition	  of	  LOOH	  does	  not	  increase	  their	  expression	  further.	  Alternatively,	  the	  lack	  of	  a	  statistically	  significant	  increase	  could	  be	  due	  to	  insufficient	  replicates	  because	  the	  clear	  trend	  with	  TET2,	  TLR-­‐2,	  and	  IL-­‐8	  shows	  slightly	  higher	  expression	  in	  PMA+LOOH	  cells	  than	  PMA	  alone.	  	  Complimentary	  to	  host	  reaction	  in	  PTL	  is	  the	  presence	  of	  subclinical	  levels	  of	  microorganisms	  ascending	  from	  the	  vaginal	  microbiome,	  but	  since	  these	  types	  of	  infections	  are	  tough	  to	  clearly	  isolate	  and	  identify	  in	  sPTL	  intrauterine	  tissue,	  focusing	  on	  the	  host	  response	  and	  attempting	  to	  identify	  receptors	  of	  innate	  immunity	  that	  are	  upregulated	  in	  sPTL	  may	  provide	  valuable	  information.	  While	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attempting	  to	  activate	  TET2,	  TLR-­‐2,	  TLR-­‐9,	  and	  IL-­‐8	  with	  PAMPs,	  we	  noticed	  there	  was	  no	  significant	  difference	  between	  PMA+LR	  groups	  compared	  to	  PMA	  groups.	  Although	  we	  had	  expected	  to	  see	  further	  increase	  of	  TET2,	  TLRs,	  and	  IL-­‐8	  in	  PMA+LR	  treated	  cells	  compared	  to	  PMA	  alone,	  we	  suspect	  there	  was	  no	  difference	  because	  L.	  rhamnosus	  is	  a	  probiotic	  strain	  of	  bacteria.	  Largely	  present	  in	  the	  gut	  as	  well	  as	  the	  vagina,	  L.	  rhamnosus	  has	  been	  found	  to	  reduce	  ROS	  production	  and	  phagocytic	  activity	  of	  neutrophils	  44.	  In	  future	  experiments,	  perhaps	  a	  more	  aggressive	  or	  pathogenic	  bacterial	  should	  be	  tested.	  Lack	  of	  a	  response	  to	  L.	  
rhamnosus	  may	  also	  have	  been	  due	  to	  an	  insufficient	  dose	  of	  LR.	  	  	  
C.	  TET2	  translocation	  	  	   TET2	  is	  a	  primary	  component	  for	  DNA	  demethylation	  as	  monocytes	  differentiate	  into	  macrophages	  18.	  We	  confirmed	  that	  TET2	  expression	  is	  increased	  during	  differentiation,	  as	  well	  as	  under	  certain	  inflammatory	  conditions.	  Since	  TET2	  is	  an	  enzyme,	  we	  needed	  a	  means	  of	  determining	  if	  TET2	  was	  activated	  in	  response	  to	  our	  treatments.	  	  Fluorescence	  immunohistochemistry	  provided	  visual	  insight	  into	  how	  TET2	  is	  activated.	  TET2	  was	  observed	  to	  be	  concentrated	  in	  the	  cytosol	  of	  control	  cells,	  but	  in	  the	  PMA,	  PMA+LOOH,	  and	  PMA+LR	  treatment	  groups,	  it	  had	  moved	  to	  the	  nucleus,	  which	  provided	  evidence	  that	  unstimulated	  TET2	  is	  localized	  to	  the	  cytosol,	  but	  upon	  activation	  translocates	  into	  the	  nucleus.	  This	  finding	  regarding	  TET2	  activation	  is	  new.	  The	  clear	  difference	  in	  TET2	  location	  in	  control	  monocytes	  versus	  treated	  macrophage	  cells	  confirms	  that	  TET2	  translocates	  from	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the	  cytosol	  into	  the	  nucleus	  upon	  differentiation	  from	  monocyte	  to	  macrophage,	  as	  well	  as	  stimulation	  with	  LOOH,	  and	  stimulation	  with	  PAMPs.	  Thus,	  TET2	  not	  only	  increases	  expression	  but	  positions	  itself	  within	  the	  nucleus	  to	  be	  functional	  on	  DNA	  as	  monocytes,	  which	  are	  circulating	  in	  peripheral	  bloodstream,	  differentiate	  and	  migrate	  into	  tissues.	  This	  has	  important	  physiological	  implications	  because	  that	  means	  macrophages	  are	  capable	  of	  rapidly	  upregulating	  a	  whole	  host	  of	  TET2-­‐specific	  genes	  when	  under	  attack	  by	  microbes	  or	  DAMPs.	  	  	  
D.	  IL-­‐8	  levels	  in	  stimulated	  THP-­‐1	  cells	  	  
	   	  	   To	  investigate	  activation	  of	  TLRs	  by	  our	  treatements,	  we	  quantified	  the	  levels	  of	  IL-­‐8	  present	  in	  cell	  supernatant	  as	  a	  representative	  down	  stream	  gene	  known	  to	  be	  increased	  by	  TLR	  activation.	  IL-­‐8	  concentration	  for	  PMA+LOOH	  treated	  cells	  correlated	  with	  gene	  expression	  studies	  in	  that	  PMA+LOOH	  exhibited	  approximately	  15	  times	  higher	  IL-­‐8	  fold	  change	  than	  PMA	  cells,	  whereas	  IL-­‐8	  concentrations	  were	  about	  6	  times	  higher.	  However,	  in	  contrast	  to	  gene	  expression	  for	  IL-­‐8	  in	  PMA+LR	  cells,	  secreted	  IL-­‐8	  concentrations	  were	  higher	  than	  PMA	  cells.	  These	  data	  demonstrate	  that	  even	  though	  TLR	  gene	  expression	  may	  not	  be	  increased	  in	  response	  to	  certain	  PAMPs	  or	  DAMPs,	  their	  activation	  is	  sufficient	  to	  stimulate	  increased	  expression	  of	  proinflammatory	  cytokines.	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E.	  Conclusions	  
	   1. TET2	  is	  expressed	  in	  immune	  cells	  of	  decidual	  tissue	  	  2. TET2	  expression	  levels	  correlate	  with	  those	  of	  TLR-­‐2	  and	  TLR-­‐9	  where	  expression	  increases	  in	  the	  order	  TNL	  <	  TL	  <	  sPTL	  <	  iPTL	  	   3. TET2	  is	  located	  in	  the	  cytoplasm	  of	  unstimulated	  THP-­‐1	  cells	  and	  in	  the	  nuclei	  of	  PMA,	  PMA+LOOH,	  and	  PMA+LR	  treated	  cells	  	   4. LR,	  which	  is	  commonly	  found	  in	  the	  vagina,	  does	  not	  increase	  gene	  expression	  of	  TET2,	  TLR-­‐2,	  TLR-­‐9,	  or	  IL-­‐8,	  nor	  does	  LOOH	  compared	  to	  PMA	  alone	  	   5. Although	  LOOH	  and	  LR	  do	  not	  increase	  gene	  expression	  of	  TLRs,	  they	  do,	  however,	  activate	  TLRs,	  as	  evidenced	  by	  significant	  increases	  of	  IL-­‐8	  production	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